<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005196.pub4" GROUP_ID="GYNAECA" ID="181604052820262417" MERGED_FROM="" MODIFIED="2016-03-23 14:24:43 +0000" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;/p&gt;&lt;p&gt;Old title: Combination chemotherapy for high risk gestational trophoblastic tumour&lt;/p&gt;" NOTES_MODIFIED="2016-03-23 14:23:18 +0000" NOTES_MODIFIED_BY="Clare Jess" REVIEW_NO="H007" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="17.2">
<COVER_SHEET MODIFIED="2016-03-23 14:24:43 +0000" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2012-11-14 16:51:58 +0000" MODIFIED_BY="Clare Jess">Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour</TITLE>
<CONTACT MODIFIED="2016-03-23 14:24:43 +0000" MODIFIED_BY="Clare Jess"><PERSON ID="12346" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Taixiang</FIRST_NAME><LAST_NAME>Wu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>txwutx@hotmail.com</EMAIL_1><URL>http://www.chictr.org</URL><MOBILE_PHONE>+86 18980604562</MOBILE_PHONE><ADDRESS><DEPARTMENT>Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 86507920</PHONE_1><PHONE_2>+86 18980604562</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-03-23 14:24:43 +0000" MODIFIED_BY="Clare Jess"><PERSON ID="BF20BDCC82E26AA2003F1F395BFBD4AC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Linyu</FIRST_NAME><LAST_NAME>Deng</LAST_NAME><EMAIL_1>dly.scu.bio@163.com</EMAIL_1><ADDRESS><DEPARTMENT>National Key Laboratory of Biotherapy and Cancer Centre</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 138 8015 6280</PHONE_1></ADDRESS></PERSON><PERSON ID="17737" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Jing</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><POSITION>Resident</POSITION><EMAIL_1>jingzhang110914@126.com</EMAIL_1><EMAIL_2>moureen123@yahoo.com.cn</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>West China Second University Hospital, West China Women's and Children's Hospital</ORGANISATION><ADDRESS_1>No. 20, 3rd section, Renmin South Road</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 85501346</PHONE_1></ADDRESS></PERSON><PERSON ID="12346" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Taixiang</FIRST_NAME><LAST_NAME>Wu</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>txwutx@hotmail.com</EMAIL_1><URL>http://www.chictr.org</URL><MOBILE_PHONE>+86 18980604562</MOBILE_PHONE><ADDRESS><DEPARTMENT>Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 86507920</PHONE_1><PHONE_2>+86 18980604562</PHONE_2></ADDRESS></PERSON><PERSON ID="16495233707895187386090810093217" ROLE="AUTHOR"><FIRST_NAME>Theresa</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Lawrie</LAST_NAME><SUFFIX>MBBCH, PhD</SUFFIX><POSITION>Senior Researcher</POSITION><EMAIL_1>tess@lawrie.com</EMAIL_1><MOBILE_PHONE>+447826939464</MOBILE_PHONE><ADDRESS><DEPARTMENT>Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group</DEPARTMENT><ORGANISATION>Royal United Hospital</ORGANISATION><ADDRESS_1>Education Centre</ADDRESS_1><CITY>Bath</CITY><ZIP>BA1 3NG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1225 720046</PHONE_1><PHONE_2>01225 720046</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-03-23 13:59:56 +0000" MODIFIED_BY="Clare Jess">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="3" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2016-03-23 14:01:45 +0000" MODIFIED_BY="Clare Jess">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-03-23 14:01:45 +0000" MODIFIED_BY="Clare Jess">
<DATE DAY="23" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>No new studies identified in this or the previous update and currently there no on-going studies. Therefore, the review is considered stable and not for future update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-11-23 15:10:50 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-03-27 11:32:07 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="4" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>Review updated. No new studies included or excluded. Conclusions unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-27 11:32:07 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="3" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Search updated. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-05-25 12:51:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>New author byline.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-05-25 12:50:49 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Minor update 13 June 08</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-10-19 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Chinese Cochrane Centre</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>West China Hospital of Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-10-19 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-10-19 13:30:09 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This review received methodological, statistical and editorial support as part of the 10/4001/12 NIHR Cochrane Programme Grant Scheme: Optimising care, diagnosis and treatment pathways to ensure cost effectiveness and best practice in gynaecological cancer: improving evidence for the NHS.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-03-23 14:23:18 +0000" MODIFIED_BY="Clare Jess">
<SUMMARY MODIFIED="2012-11-14 16:52:31 +0000" MODIFIED_BY="Taixiang Wu">
<TITLE MODIFIED="2012-10-18 14:10:55 +0100" MODIFIED_BY="[Empty name]">Combinations of anti-cancer drugs to treat high-risk cancers arising from the placenta, known as high-risk gestational trophoblastic neoplasia (GTN)</TITLE>
<SUMMARY_BODY MODIFIED="2012-11-14 16:52:31 +0000" MODIFIED_BY="Taixiang Wu">
<P>GTN is a cancer that most often arises after a molar pregnancy but can arise after any type of pregnancy. Molar pregnancies occur due to abnormal growth of placental tissue that is usually benign and treated by evacuation of the womb (D&amp;C). However, in less than 10% of molar pregnancies in the UK, the growth remains after D&amp;C and transforms into a cancer (GTN) that needs treatment with anti-cancer drugs (chemotherapy). GTN can be low-risk or high-risk. Anti-cancer drugs are very effective, especially in low-risk GTN, which is usually cured with single-drug treatment. However, high-risk GTN needs to be treated with combinations of anti-cancer drugs for the best effect. These drugs can produce toxic side effects that are more likely to occur when used in combination with each other. The most commonly administered drug combination is abbreviated as EMA/CO, which stands for <U>E</U>toposide, <U>M</U>ethotrexate, <U>A</U>ctinomycin D, <U>C</U>yclophosphamide and <U>O</U>ncovin® (vincristine), but several other combinations are also in use.</P>
<P>We undertook this review to try to determine which combination/s of drugs are the most effective for the first-line drug treatment of high-risk GTN, and with the least side effects. We found only one small, older study that compared a drug combination abbreviated as CHAMOCA with one called MAC. The CHAMOCA regimen, which is no longer recommended for GTN treatment, was found to be extremely toxic to the blood and bone marrow, with no greater effect against the cancer than the MAC regimen. Based on the available evidence, it is currently not possible to determine whether EMA/CO is the most effective and least toxic drug combination as no high-quality studies have been conducted comparing this combination with other combinations. GTN is a rare cancer and so studies in this field are difficult to conduct, therefore researchers need to collaborate in order to produce the necessary high-quality evidence.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-03-23 14:21:23 +0000" MODIFIED_BY="Clare Jess">
<ABS_BACKGROUND MODIFIED="2012-11-14 16:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>This is an update of the original review that was published in The Cochrane Database of Systematic Reviews, 2009, Issue 2. Gestational trophoblastic neoplasia (GTN) are malignant disorders of the placenta that include invasive hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). Choriocarcinoma and invasive hydatidiform mole respond well to chemotherapy: low-risk tumours are treated with single-agent chemotherapy (e.g. methotrexate or actinomycin D), whereas high-risk tumours are treated with combination chemotherapy (e.g. EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine)). Various drug combinations may be used for high-risk tumours; however, the comparative efficacy and safety of these regimens is not clear.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-11-14 16:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and safety of combination chemotherapy in treating high-risk GTN.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-03-23 14:21:23 +0000" MODIFIED_BY="Clare Jess">
<P>For the original review, we searched the Cochrane Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL; Issue 2, 2008), MEDLINE, EMBASE and CBM in May 2008. For the updated review, we searched Cochrane Group Specialised Register, CENTRAL, MEDLINE and EMBASE to September 2012 and on 1 June 2015. In addition, we searched online clinical trial registries for ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-10-18 14:08:57 +0100" MODIFIED_BY="Taixiang Wu">
<P>Randomised controlled trials (RCTs) and quasi-RCTs comparing first-line combination chemotherapy interventions in women with high-risk GTN. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-11-14 16:52:13 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently collected data using a data extraction form. Meta-analysis could not be performed as we included only one study.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-11-14 16:52:15 +0000" MODIFIED_BY="[Empty name]">
<P>We included one RCT of 42 women with high-risk GTN who were randomised to MAC (methotrexate, actinomycin D and chlorambucil) or the modified CHAMOCA regimen (cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, doxorubicin, melphalan and vincristine). There were no statistically significant differences in efficacy of the two regimens; however women in the MAC group experienced statistically significantly less toxicity overall and less haematological toxicity than women in the CHAMOCA group. During the study period, six women in the CHAMOCA group died compared with one in the MAC group. This study was stopped early due to unacceptable levels of toxicity in the CHAMOCA group. We identified no RCTs comparing EMA/CO with MAC or other chemotherapy regimens.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-11-14 16:52:20 +0000" MODIFIED_BY="[Empty name]">
<P>CHAMOCA is not recommended for GTN treatment as it is more toxic and not more effective than MAC. EMA/CO is currently the most widely used first-line combination chemotherapy for high-risk GTN, although this regimen has not been rigorously compared to other combinations such as MAC or FAV in RCTs. Other regimens may be associated with less acute toxicity than EMA/CO; however, proper evaluation of these combinations in high-quality RCTs that include long-term surveillance for secondary cancers is required. We acknowledge that, given the low incidence of GTN, RCTs in this field are difficult to conduct, hence multicentre collaboration is necessary.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-03-23 14:23:18 +0000" MODIFIED_BY="Clare Jess">
<BACKGROUND MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<CONDITION MODIFIED="2012-11-14 16:52:55 +0000" MODIFIED_BY="Gail Quinn">
<P>This is an update of the original review that was published in The Cochrane Database of Systematic Reviews, 2009, Issue 2<I>. </I>Gestational trophoblastic neoplasia (GTN) together with hydatidiform moles (HM) are collectively known as gestational trophoblastic disease (GTD), a spectrum of tumours that arise from placental tissue. GTN represents the malignant forms of the disease that includes invasive mole, choriocarcinoma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT) (<LINK REF="REF-Lurain-2011" TYPE="REFERENCE">Lurain 2011</LINK>). GTNs most frequently occur following a molar pregnancy (<LINK REF="REF-Seckl-2009a" TYPE="REFERENCE">Seckl 2009a</LINK>); however, they may occur following any antecedent pregnancy including a term pregnancy, miscarriage or an ectopic pregnancy.</P>
<P>HMs are benign tumours that are described as partial or complete based on the morphological, karyotypic and clinical features (<LINK REF="REF-Szulman-1978" TYPE="REFERENCE">Szulman 1978</LINK>). Complete moles (CMs) are paternally derived and have a diploid karyotype (usually 46 XX) whereas partial moles (PMs) usually have a triploid karyotype (<LINK REF="REF-Fisher-2009" TYPE="REFERENCE">Fisher 2009</LINK>). CMs are associated with total hydatidiform enlargement of the villi, whereas the hydatidiform changes of the villi in PMs tend to be localised (<LINK REF="REF-Driscoll-1981" TYPE="REFERENCE">Driscoll 1981</LINK>). The p57 gene is not present in CMs as p57 is paternally imprinted but maternally expressed, therefore p57 immunostaining can distinguish CMs from PMs or hydropic abortions (<LINK REF="REF-Popiolek-2006" TYPE="REFERENCE">Popiolek 2006</LINK>). HMs usually resolve spontaneously following one or more uterine evacuations; however, in approximately 6% to 20% of CMs and 0.5% to 1% of PMs the disease persists and transforms into GTN (<LINK REF="REF-Seckl-2009a" TYPE="REFERENCE">Seckl 2009a</LINK>). Overall, <LINK REF="REF-Seckl-2009a" TYPE="REFERENCE">Seckl 2009a</LINK> estimates that 8% of HMs in the UK will transform and need chemotherapy.</P>
<P>The incidence of GTD varies geographically with some countries showing an increase in GTD rates over time, while others showing a decline (<LINK REF="REF-Lee-2009" TYPE="REFERENCE">Lee 2009</LINK>). Europe, Japan and North America report GTD rates of &#8804; 1/1000 pregnancies, whereas India, Turkey and Indonesia report the highest rates (<LINK REF="REF-Lee-2009" TYPE="REFERENCE">Lee 2009</LINK>). A study carried out to determine the incidence rate of GTD in south-east Anatolia (Turkey) from July 1998 to October 2003 reported that out of 6016 deliveries, 73 cases of GTD were identified, giving an incidence of 12/1000 deliveries. Of these GTD cases, two (2.7%) had invasive mole and five (6.9%) had choriocarcinoma (<LINK REF="REF-Harma-2005" TYPE="REFERENCE">Harma 2005</LINK>), which is equivalent to an incidence of GTN in this region of 1/1000 deliveries.</P>
<P>Although the aetiology of GTN is not well understood, the occurrence of this tumour has been associated with several factors including the extremes of reproductive age (younger than 20 years and older than 40 years), previous HM and particular ABO blood groups (<LINK REF="REF-Bagshawe-1986" TYPE="REFERENCE">Bagshawe 1986</LINK>; <LINK REF="REF-Hayashi-1982" TYPE="REFERENCE">Hayashi 1982</LINK>). In addition, ethnicity, poor nutrition, viral infections and environmental factors may play a role (<LINK REF="REF-Lee-2009" TYPE="REFERENCE">Lee 2009</LINK>).</P>
<P>The three types of GTN have distinct morphological features. Invasive moles and choriocarcinomas arise from fetal tissue within the maternal host and are composed of both syncytiotrophoblastic and cytotrophoblastic cells (<LINK REF="REF-WHO-1983" TYPE="REFERENCE">WHO 1983</LINK>). Invasive moles have the same histological features as CMs but are characterised by myometrial invasion without involvement of intervening endometrial stroma (<LINK REF="REF-Lurain-1982" TYPE="REFERENCE">Lurain 1982</LINK>). Choriocarcinomas have a unique histology distinct from that of moles: microscopically, the neoplasm is composed of a disordered array of syncytiotrophoblastic and cytotrophoblastic elements, frequent mitoses and multinucleated giant cells (<LINK REF="REF-Mazur-1987" TYPE="REFERENCE">Mazur 1987</LINK>). Vascular invasion occurs early, with resultant metastases to the lungs, vagina, brain, kidneys, liver and gastrointestinal tract (<LINK REF="REF-Decherney-2003" TYPE="REFERENCE">Decherney 2003</LINK>). PSTTs are derived from intermediate trophoblast cells of the placenta, which are identified by the secretion of placental lactogen and small amounts of &#946;-human chorionic gonadotrophin (&#946;-hCG) (<LINK REF="REF-Kurman-1984" TYPE="REFERENCE">Kurman 1984</LINK>).</P>
<P>GTNs are characterised by aggressive biological cell behaviour and a propensity for widespread metastases, especially choriocarcinomas (<LINK REF="REF-Song-2004" TYPE="REFERENCE">Song 2004</LINK>). All GTNs secrete hCG, which is a unique and characteristic tumour marker that can be used in the monitoring of treatment and in follow-up (<LINK REF="REF-Pastorfide-1974" TYPE="REFERENCE">Pastorfide 1974</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>GTNs are the only disseminated solid tumours that are highly curable by chemotherapy (<LINK REF="REF-Schorge-2003" TYPE="REFERENCE">Schorge 2003</LINK>), except for PSTTs and ETTs, which are rare and relatively resistant to chemotherapy (<LINK REF="REF-Lurain-2011" TYPE="REFERENCE">Lurain 2011</LINK>). The majority of invasive moles and choriocarcinomas will be cured with first-line chemotherapy; however, some will persist or metastasise, thereby needing secondary treatments, adjuvant treatments (such as surgery or radiotherapy) or a combination. <LINK REF="REF-Bagshawe-1976" TYPE="REFERENCE">Bagshawe 1976</LINK> introduced a scoring system to identify those tumours that were at a higher risk of metastases or persistence, and the World health Organization (WHO) subsequently adapted this system (<LINK REF="REF-WHO-1983" TYPE="REFERENCE">WHO 1983</LINK>) to classify tumours as low-risk (score &#8804; 4), medium risk (score 5 to 7) and high-risk (score &#8805; 8) based on various prognostic factors including: age, antecedent pregnancy, interval since antecedent pregnancy, hCG level, ABO blood group, largest tumour site(s) of metastases, site of metastases and previous chemotherapy. More recently, the International Federation of Obstetrics and Gynecology (FIGO) has modified the WHO system to include low-risk (score &#8804; 6) and high-risk (score &#8805; 7) only (<LINK REF="REF-FIGO-2009" TYPE="REFERENCE">FIGO 2009</LINK>; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The scoring system of FIGO differs from the WHO system in that the ABO blood group risk factor is eliminated and the risk factor for liver metastasis is upgraded from two, to highest group, four. FIGO recommends denoting the anatomical stage (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>) and the risk score for individual patients (<LINK REF="REF-FIGO-2009" TYPE="REFERENCE">FIGO 2009</LINK>).</P>
<P>Low-risk GTN is usually treated with single-agent chemotherapy and cure rates approximate 100% (<LINK REF="REF-Seckl-2009b" TYPE="REFERENCE">Seckl 2009b</LINK>). Both methotrexate (with folinic acid) and low-dose actinomycin D are effective (<LINK REF="REF-Alazzam-2012a" TYPE="REFERENCE">Alazzam 2012a</LINK>). For high-risk GTN, appropriate and timely treatment can prevent life-threatening complications (<LINK REF="REF-Decherney-2003" TYPE="REFERENCE">Decherney 2003</LINK>). This treatment involves multi-agent or combination chemotherapy with or without adjuvant radiotherapy and surgery, and cure rates with current regimens are estimated to be around 80% to 90% (<LINK REF="REF-Goldstein-2012" TYPE="REFERENCE">Goldstein 2012</LINK>).</P>
<P>The following regimens have been described:</P>
<UL>
<LI>EMA/CO: etoposide, methotrexate, actinomycin D (EMA) plus cyclophosphamide and vincristine (CO) (<LINK REF="REF-Newlands-1986" TYPE="REFERENCE">Newlands 1986</LINK>; <LINK REF="REF-Bower-1997" TYPE="REFERENCE">Bower 1997</LINK>; <LINK REF="REF-Newlands-1998" TYPE="REFERENCE">Newlands 1998</LINK>; <LINK REF="REF-Tang-2003" TYPE="REFERENCE">Tang 2003</LINK>; <LINK REF="REF-Seckl-2009b" TYPE="REFERENCE">Seckl 2009b</LINK>; <LINK REF="REF-Goldstein-2012" TYPE="REFERENCE">Goldstein 2012</LINK>);</LI>
<LI>MAC: methotrexate, actinomycin D, cyclophosphamide or chlorambucil (CB1348) (<LINK REF="REF-Hammond-1973" TYPE="REFERENCE">Hammond 1973</LINK>; <LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>);</LI>
<LI>EMA/EP: etoposide, methotrexate, actinomycin D (EMA) plus etoposide and cisplatin (EP) (<LINK REF="REF-Ghaemmaghami-2004" TYPE="REFERENCE">Ghaemmaghami 2004</LINK>; <LINK REF="REF-Cyriac-2011b" TYPE="REFERENCE">Cyriac 2011b</LINK>);</LI>
<LI>CHAMOCA or CHAMOMA: cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, doxorubicin, melphalan and vincristine (<LINK REF="REF-Bagshawe-1977" TYPE="REFERENCE">Bagshawe 1977</LINK>; <LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>);</LI>
<LI>EMA: etoposide, methotrexate and actinomycin D (<LINK REF="REF-Matsui-2000" TYPE="REFERENCE">Matsui 2000</LINK>; <LINK REF="REF-Dobson-2000" TYPE="REFERENCE">Dobson 2000</LINK>);</LI>
<LI>FA (5-fluorouracil (5-FU) and actinomycin D) or FAV (5-FU, actinomycin D and vincristine) (<LINK REF="REF-Zhao-2009" TYPE="REFERENCE">Zhao 2009</LINK>; <LINK REF="REF-Feng-2011" TYPE="REFERENCE">Feng 2011</LINK>); and</LI>
<LI>MEF (methotrexate, etoposide, 5-FU) (<LINK REF="REF-Wang-2006" TYPE="REFERENCE">Wang 2006</LINK>).</LI>
</UL>
</INTERVENTION>
<THEORY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>Most high-risk GTNs will respond to various chemotherapy regimens. The MAC regimen was commonly used in the 1970s and 1980s until etoposide was found to have high activity against GTNs (<LINK REF="REF-Goldstein-2012" TYPE="REFERENCE">Goldstein 2012</LINK>). CHAMOCA was compared with MAC but was found to be associated with significantly more haematological toxicity (<LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>) and subsequently abandoned. One UK study reported using EMA/CO (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) in 272 women with high-risk GTN (primary and secondary), inducing remission rates of 86% of women (<LINK REF="REF-Bower-1997" TYPE="REFERENCE">Bower 1997</LINK>; <LINK REF="REF-Newlands-1998" TYPE="REFERENCE">Newlands 1998</LINK>).Thereafter EMA/CO became the preferred first-line combination regimen in North America (<LINK REF="REF-Goldstein-2012" TYPE="REFERENCE">Goldstein 2012</LINK>), Europe (<LINK REF="REF-Seckl-2009b" TYPE="REFERENCE">Seckl 2009b</LINK>) and elsewhere. However, 5-FU combinations are reported to be preferred in parts of China (<LINK REF="REF-Feng-2011" TYPE="REFERENCE">Feng 2011</LINK>). Currently, EMA/EP is recommended for salvage therapy of EMA/CO-resistant tumours (<LINK REF="REF-Goldstein-2012" TYPE="REFERENCE">Goldstein 2012</LINK>; <LINK REF="REF-Seckl-2009b" TYPE="REFERENCE">Seckl 2009b</LINK>); however, it has also been used for first-line therapy (<LINK REF="REF-Ghaemmaghami-2004" TYPE="REFERENCE">Ghaemmaghami 2004</LINK>; <LINK REF="REF-Cyriac-2011b" TYPE="REFERENCE">Cyriac 2011b</LINK>).</P>
<P>Combination chemotherapy regimens are frequently associated with side effects that may result in significant morbidity and treatment delays or changes. Some agents, such as etoposide, have been associated with an increased risk of secondary tumours, including acute myeloid leukaemia (AML), colon cancer, breast cancer and melanoma (<LINK REF="REF-Schorge-2003" TYPE="REFERENCE">Schorge 2003</LINK>). The main side effects of EMA/CO are haematological toxicity, gastrointestinal toxicity and reversible alopecia (<LINK REF="REF-Zhao-2000" TYPE="REFERENCE">Zhao 2000</LINK>; <LINK REF="REF-Seckl-2010" TYPE="REFERENCE">Seckl 2010</LINK>). Although the most favoured initial chemotherapy regimen in high-risk GTN patients is EMA/CO, the relative side effects of this regimen compared to other chemotherapy regimens are unclear.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>We originally conducted this review in 2006 with the aim of comparing all RCTs of combination chemotherapy used as treatment for high-risk GTN, to determine their relative efficacies and safety. However, we were only able to include one study (CHAMOCA versus MAC; <LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>) in the original review. Furthermore we identified no RCTs comparing the more frequently used combinations (e.g. EMA/CO and MAC). Combination chemotherapy regimens may be associated with side effects that result in significant morbidity and treatment delays or changes, therefore comparing these regimens with respect to efficacy and toxicity is important. We continue to update this review periodically, in order to identify new studies that may be helpful in providing treatment guidelines for these rare tumours. Chemotherapy for low-risk GTN and salvage chemotherapy for recurrent and resistant GTN are the subject of separate reviews (<LINK REF="REF-Alazzam-2012a" TYPE="REFERENCE">Alazzam 2012a</LINK>; <LINK REF="REF-Alazzam-2012b" TYPE="REFERENCE">Alazzam 2012b</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>To determine the efficacy and safety of combination chemotherapy in the treatment of high-risk GTN.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-03-23 14:23:18 +0000" MODIFIED_BY="Clare Jess">
<SELECTION_CRITERIA MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<CRIT_STUDIES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>Any randomised controlled trials (RCTs) and quasi-RCTs comparing first-line combination chemotherapy regimens for the treatment of high-risk GTN.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>Inclusion criteria<BR/>
</P>
<UL>
<LI>Women diagnosed with high-risk GTN who had a pathological diagnosis and a high-risk prognostic score as determined by any prognostic scoring system, such as FIGO (<LINK REF="REF-Kohorn-2001" TYPE="REFERENCE">Kohorn 2001</LINK>), WHO (<LINK REF="REF-WHO-1983" TYPE="REFERENCE">WHO 1983</LINK>) or Bagshawe (<LINK REF="REF-Bagshawe-1976" TYPE="REFERENCE">Bagshawe 1976</LINK>).</LI>
</UL>
<P>Exclusion criteria<BR/>
</P>
<UL>
<LI>Women with PSTT.</LI>
<LI>Women receiving secondary or salvage chemotherapy for recurrent or resistant GTN.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>Combination chemotherapy regimens compared with other combination chemotherapy (e.g. EMA/CO versus MAC).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Death from any cause (overall survival).</LI>
<LI>Death from cancer (cancer-specific survival).</LI>
<LI>Progression or recurrence of the cancer (progression-free survival).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<UL>
<LI>Level of &#946;-hCG.</LI>
<LI>Adverse events, according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines (<LINK REF="REF-ICH-1997" TYPE="REFERENCE">ICH 1997</LINK>), Common Terminology Criteria for Adverse Events (CTCAE) guidelines (<LINK REF="REF-CTCAE-2010" TYPE="REFERENCE">CTCAE 2010</LINK>) or as defined by the investigators.</LI>
<LI>Secondary cancers.</LI>
<LI>Quality of life (QoL).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-03-23 14:23:18 +0000" MODIFIED_BY="Clare Jess">
<ELECTRONIC_SEARCHES MODIFIED="2016-03-23 14:23:18 +0000" MODIFIED_BY="Clare Jess">
<P>For the original review, we searched the following databases: Cochrane Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, Issue 2, 2008); MEDLINE (from 1966 to 15 June 2008); EMBASE (from 1980 to 15 June 2008); Chinese Biomedical database (CBM; from 1978 to 15 June 2008 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)) and China National Knowledge Infrastructure (CNKI; from 1997 to 15 June 2008). For the updated review, we searched Cochrane Group Specialised Register, CENTRAL (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), MEDLINE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) and EMBASE (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) (to 12 September 2012 and on 1 June 2015)</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>We searched the International Society for the Study of Trophoblastic Diseases (ISSTD) website. In addition, we searched the following online registries for ongoing trials (15 June 2008 and 17 September 2012):</P>
<UL>
<LI>Australian New Zealand Clinical Trial Registry (<A HREF="http://www.anzctr.org.au/">www.anzctr.org.au/</A>)</LI>
<LI>Chinese Clinical Trial Register (<A HREF="http://www.chictr.org">www.chictr.org</A>)</LI>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>)</LI>
<LI>Current Controlled Trials (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>)</LI>
<LI>WHO ICTRP Search Portal (<A HREF="http://www.who.int/ictrp/network/en/index.html">www.who.int/ictrp/network/en/index.html</A>)</LI>
<LI>the National Research Register (<A HREF="http://www.update-software.com">www.update-software.com</A>)</LI>
<LI>the ISRCTN Register (<A HREF="http://isrctn.org">isrctn.org</A>)</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<STUDY_SELECTION MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>Two review authors (DLY, XY) sifted the results of the original search and TL sifted the updated search for potentially relevant trials. DLY and XY independently assessed trials for inclusion in the review. Differences were resolved by discussion between review authors (DLY, XY, WT). Failure to resolve differences would have been brought to the attention of the Contact Editor (WT) responsible for the review and a majority decision taken.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>DLY and XY independently extracted data using a piloted data extraction form. Extracted data on study characteristics included methods, participants, interventions and outcomes. Differences were resolved by discussion between the review authors. Failure to resolve differences would have been brought to the attention of the Contact Editor responsible for the review and a majority decision taken. If data from the trial reports were insufficient or missing the authors would have been contacted for additional information.</P>
<P>Where possible we extracted data to allow for an intention-to-treat analysis (the analysis included all the participants in the groups to which they were originally randomly assigned). If the number randomised and the number analysed were inconsistent, the percentage lost to follow-up was calculated. For dichotomous outcomes, we recorded the number of participants experiencing the event in each group of the trial out of the number in whom the event was assessed in each group. For continuous outcomes, we extracted the arithmetic mean and standard deviation (SD) for each group.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>Using The Cochrane Collaboration's tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), we assessed the following:</P>
<OL>
<LI>selection bias: random sequence generation and allocation concealment;</LI>
<LI>performance bias: blinding of participants and personnel (patients and treatment providers);</LI>
<LI>detection bias: blinding of outcome assessment;</LI>
<LI>attrition bias: incomplete outcome data;</LI>
<LI>reporting bias: selective reporting of outcomes;</LI>
<LI>other possible sources of bias.</LI>
</OL>
<P>We classified the risk of these biases as 'low', 'high' or 'unclear' for each included study. For more details see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>Only dichotomous data were available for this review, therefore we used the risk ratio (RR) with 95% confidence intervals (CIs) for all outcomes. In future versions of this review, if other types of outcome data are available, we will also use the following measures of the effect of treatment:</P>
<UL>
<LI>for time to event data, the hazard ratio (HR) with 95% CIs; and</LI>
<LI>for continuous outcomes that use the same scales, the mean difference (MD) between treatment arms with 95% CIs; for trials that measured the same outcome but use different scales, we plan to use the standardised mean difference (SMD).</LI>
</UL>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>Heterogeneity among trials would have been assessed by visual inspection of the forest plots and by formal statistical tests for heterogeneity, including the T<SUP>2</SUP>, I<SUP>2</SUP> and Chi<SUP>2</SUP> statistics (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>); however there were insufficient trials for meta-analyses. In future versions of this review, we will regard heterogeneity as substantial if T<SUP>2</SUP> is greater than zero and either I<SUP>2</SUP> is greater than 30% or there is a low P value (&lt; 0.10) in the Chi<SUP>2</SUP> test for heterogeneity. </P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and used the random-effects model to produce an overall summary of the mean treatment effect across pooled studies (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>We planned to perform subgroup analyses in order to explore effect size differences according to:</P>
<UL>
<LI>prognostic scores, for example high-risk (scores of 7 to 13) and very high-risk (scores &gt;13); and</LI>
<LI>duration of follow-up.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-10-19 10:00:48 +0100" MODIFIED_BY="Gail Quinn">
<P>Had there been sufficient included studies, sensitivity analyses would have been performed to examine the effects of lower methodological quality studies on the results and to explore the reasons for heterogeneity.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-11-23 14:59:39 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-11-23 14:59:39 +0000" MODIFIED_BY="[Empty name]">
<P>There were no new studies to include (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) in the updated versions of the review. We included one prospective randomised study (<LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>) in the original review. This North American study was a multi-institutional study conducted between November 1981 and May 1986. Prognostic risk factors were evaluated using the criteria of Hammond (<LINK REF="REF-Hammond-1973" TYPE="REFERENCE">Hammond 1973</LINK>) and the prognostic score from Wong (<LINK REF="REF-Wong-1986" TYPE="REFERENCE">Wong 1986</LINK>). Forty-two women entered the study, with 22 receiving the MAC regimen and 20 receiving a modified CHAMOCA (or CHAMOMA) regimen. The regimens consisted of methotrexate, actinomycin D, chlorambucil (MAC) or methotrexate, actinomycin D, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine (CHAMOCA). Each regimen was repeated every 21 days with a window of 12 to 14 days or 10 to 14 days between courses, respectively. If there was cerebral or hepatic metastasis, radiotherapy was administered with the commencement of chemotherapy. Where treatment failed, surgical procedures, chemotherapy or both, were initiated as directed by the principal investigator. Outcomes evaluated included remission (primary or secondary), death from the disease, treatment failures, the number of courses to achieve normal hCG titre, haematological toxicity and total toxicity were evaluated in this study. Treatment failure was measured by a plateau or rising hCG titre or a new metastasis.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-11-23 14:57:51 +0000" MODIFIED_BY="[Empty name]">
<P>The <LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK> study randomly allocated 42 patients into two groups; however, the randomisation procedure was not described and we could not determine whether allocation concealment or blinding was used. Selection bias, performance bias and detection bias may therefore be present in this study. No patients withdrew and there was no loss to follow-up. Baseline 'risk' characteristics were similar in each allocation group; however the mean age of participants was not described. As several aspects of the methodology of this study were unclear, we considered it to be at an unclear risk of bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<P>Only one study (<LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>), comparing MAC with the modified CHAMOCA regimen, was included in this review. The results of this study were as follows:</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<P>Death rates were 4% (1 out of 22) and 30% (6 out of 20) for the MAC and CHAMOCA treatment groups, respectively (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Primary remission rates were 73% (16 out of 22) and 65% (13 out of 20), respectively and secondary remission rates were 23% (5 out of 22) and 5% (1 out of 20), respectively. These death and remission rate differences were not statistically significant (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Primary treatment with MAC failed in six (27.3%) women. Five of these women received a total abdominal hysterectomy or the CHAMOMA regimen and survived; one woman died of seizure and aspiration, having achieved normal hCG titres and normal laboratory data. Primary treatment with CHAMOCA failed in seven women (35%); one of these women received a thoracotomy with additional chemotherapy and survived. The remaining six women received chemotherapy, adrenal resection or total abdominal hysterectomy but died of the disease.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>Severe toxicity (grade 3 to 4) occurred significantly less frequently with the MAC regimen compared with the CHAMOCA regimen (P = 0.014; 11 out of 22 women (50%) versus 18 out of 20 women (90%), respectively; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). These events were life-threatening in two out of 22 (9%) and eight out of 20 (45%) women, respectively. Similarly, severe haematological toxicity (grade 3 to 4) occurred significantly less frequently with the MAC regimen than with the CHAMOCA regimen (P = 0.004; eight out of 22 women (36%) versus 17 out of 20 women (85%), respectively; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Taixiang Wu">
<SUMMARY_OF_RESULTS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>Only one RCT (<LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>) comparing two combinations of chemotherapy for high-risk GTN was identified and could be included. This study was at an unclear risk of bias. Overall, 42 women were enrolled and randomised to receive the MAC regimen or the modified CHAMOCA regimen. Not all review outcomes could be assessed for this comparison. However, the MAC regimen was at least as effective as the modified CHAMOCA regimen, and statistically significantly less toxic overall (P = 0.014), and to the bone marrow (P = 0.004).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>The <LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK> trial was closed when just over half the study sample had been recruited due to a statistically significant increase in severe haematological toxicity in the CHAMOCA group. The quality of evidence relating to CHAMOCA toxicity was good, despite the fact that <LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK> was an older study and more modern treatment consists of bone marrow support with granulocyte-colony stimulating factor (G-CSF) frequently being used to prevent and treat haematological complications of chemotherapy for GTN (<LINK REF="REF-Seckl-2010" TYPE="REFERENCE">Seckl 2010</LINK>). However, the fact that the CHAMOCA regimen was not shown to be more effective than MAC means that no further studies of this significantly more toxic regimen are necessary.</P>
<P>EMA/CO is the preferred regimen for treating high-risk GTN; however high-quality evidence in support of this is still lacking. There have been no RCTs comparing EMA/CO and MAC, for example. Retrospective studies have reported primary remission rates for EMA/CO ranging from 54% to 91% (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). <LINK REF="REF-Newlands-1998" TYPE="REFERENCE">Newlands 1998</LINK> described the results of 272 consecutive patients treated with EMA/CO, including 121 for secondary/salvage treatment: the median follow-up duration was 4.5 years (range 1 to 16 years) and the cumulative five-year survival rate was 86.2% (95% CI 81.9% to 90.5%). Drug resistance occurred in 47 out of 272 patients (17%) and 34 patients died (12.5%), 31 from GTN and three from other causes. The investigators noted a significant increase in secondary tumours including AML, colon cancer, melanoma and breast cancer compared with expected rates (P = 0.011).</P>
<P>
<LINK REF="REF-Kim-1998" TYPE="REFERENCE">Kim 1998</LINK> reported on a cohort of 227 patients with high-risk GTN who were treated with four different chemotherapy regimens during the period 1971 to 1995, including MA (methotrexate, folinic acid and actinomycin-D) and MAC from 1971 to 1982, CHAMOCA from 1982 to 1985 and EMA/CO from 1985 to 1995. Mean age and risk scores (mean, 10.6) of these treatment groups were comparable; however, it is not clear whether these women were all undergoing primary treatment. The remission rate of the EMA/CO regimen was 91% (87 out of 96) compared with the remission rates of 63% (31 out of 49), 68% (27 out of 40) and 76% (32 out of 45) for MA, MAC and CHAMOCA, respectively, and remission was achieved in fewer courses in the EMA/CO group. Nine deaths (9.4%) occurred in the EMA/CO group compared with 18 (37%), 13 (33%) and 10 (22%) in the MA, MAC and CHAMOCA groups, respectively. Toxicity was considered to be lower in the EMA/CO group; however, these are not detailed in the report.</P>
<P>
<LINK REF="REF-Lurain-2010" TYPE="REFERENCE">Lurain 2010</LINK> conducted a retrospective study of 40 women with metastatic high-risk GTN who were treated with EMA/CO between 1986 and 2009; 26 women underwent primary treatment and 14 underwent secondary treatment following failed single-agent therapy. Primary remission rates for primary and secondary treatment groups were 62% (16 out of 26) and 50% (7 out of 14), respectively; however, two women in the primary treatment group relapsed soon after remission, reducing the durable remission rate to 54% for primary treatment. The primary remission rates in <LINK REF="REF-Lurain-2010" TYPE="REFERENCE">Lurain 2010</LINK> are thus the lowest reported with EMA/CO treatment, although salvage chemotherapy for relapsed and resistant cases resulted in an overall survival of 90% in this study.</P>
<P>More recent data on other regimens are limited; however, in women diagnosed with high-risk GTN in Hungary between 1977 and 2010, <LINK REF="REF-F_x00fc_l_x00f6_p-2012" TYPE="REFERENCE">Fülöp 2012</LINK> reports primary remission rates of 93% and 94% for the MAC (110 out of 118 women) and bleomycin, etoposide and cisplatin (BEP) (16 out of 17 women) regimens, respectively. The EMA/CO regimen, introduced in 1993, achieved a primary remission rate of 81% (21 out of 26 women). Mean risk scores for these three groups were 11.5 (MAC), 15.5 (BEP) and 13.2 (EMA/CO). Overall survival was 96.6%.</P>
<P>Toxicity from EMA/CO is often described as well tolerated; however all 56 patients in <LINK REF="REF-Cagayan-2012" TYPE="REFERENCE">Cagayan 2012</LINK> experienced adverse drug reactions, with haematological toxicity occurring in 36%. In <LINK REF="REF-Chauhan-2010" TYPE="REFERENCE">Chauhan 2010</LINK>, two women died from acute haematological toxicity (<LINK REF="REF-Chauhan-2010" TYPE="REFERENCE">Chauhan 2010</LINK>). Although stem cell support with G-CSF may be used to prevent or reduce myelosuppression, it is very expensive and not always an option, particularly in developing countries where the bulk of GTN disease occurs.</P>
<P>In addition, the long-term risk of secondary cancers is still to be determined. Etoposide-related secondary leukaemias have a significantly worse prognosis that other types of leukaemia (<LINK REF="REF-Ezoe-2012" TYPE="REFERENCE">Ezoe 2012</LINK>), therefore it is important to understand the risk to patients with high-risk GTN who undergo treatment with this agent. The risk of etoposide-induced AML is related to the cumulative drug dose and possibly the dose method (higher dose frequency or prolonged duration of treatment) (<LINK REF="REF-Ezoe-2012" TYPE="REFERENCE">Ezoe 2012</LINK>). Furthermore, it may be increased when combined with high-dose platinum agents or concomitant radiotherapy (<LINK REF="REF-Ezoe-2012" TYPE="REFERENCE">Ezoe 2012</LINK>). As etoposide/cisplatin regimens (e.g. EMA/EP) are being used more frequently as primary (<LINK REF="REF-Cyriac-2011b" TYPE="REFERENCE">Cyriac 2011b</LINK>; <LINK REF="REF-Ghaemmaghami-2004" TYPE="REFERENCE">Ghaemmaghami 2004</LINK>) or salvage therapy (<LINK REF="REF-Newlands-2000" TYPE="REFERENCE">Newlands 2000</LINK>) (or both), researchers and clinicians should ensure that adequate long-term follow-up and surveillance for secondary cancers is conducted.</P>
<P>The importance of randomising participants to treatment groups in studies of chemotherapy interventions cannot be over-emphasised. Baseline differences between study groups in prognostic risk scores, brain and liver metastases, surgery and adjuvant therapies (e.g. G-CSF or radiotherapy), and in those undergoing primary or secondary treatment may have a substantial impact on remission, survival and toxicity rates, therefore trials comparing chemotherapy regimens need to control for these variables.</P>
<P>We consider the available evidence to be incomplete and believe that there is a need for carefully planned and well-conducted, multicentred RCTs to determine the most clinically effective, cost-effective and least toxic therapy for high-risk GTN. The possible regimens with which EMA/CO could be compared to in these studies include MAC, FAV and EMA/EP.</P>
</APPLICABILITY_OF_FINDINGS>
<POTENTIAL_BIASES MODIFIED="2012-10-19 11:12:17 +0100" MODIFIED_BY="[Empty name]">
<P>To our knowledge there were no potential biases in the review process.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>CHAMOCA is not recommended for GTN treatment. EMA/CO is currently the most widely used first-line combination chemotherapy for high-risk GTN, although this regimen has not been rigorously compared in RCTs to other combinations, such as MAC or FAV. Other regimens may be reasonable alternatives to EMA/CO; however, there is no good evidence to support this and proper evaluation in high-quality RCTs that include long-term surveillance for secondary cancers is required. We acknowledge that, given the low incidence of GTN, RCTs in this field are difficult to conduct, hence multicentre collaboration is necessary.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Taixiang Wu">
<P>A rigorously designed, international multicentre RCT is required to evaluate EMA/CO chemotherapy versus other combination chemotherapies for GTN. Baseline data should include risk scores, metastases, adjuvant therapies, and whether the participants have primary high-risk GTN or whether they are originally low-risk cases that have failed single-agent therapy. Outcomes should include overall survival, progression-free survival, hCG titres, toxicity, QoL and cost. Toxicity should be critically assessed using <LINK REF="REF-CTCAE-2010" TYPE="REFERENCE">CTCAE 2010</LINK> guidelines, and long-term surveillance should be conducted for secondary cancers.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-03-23 14:22:18 +0000" MODIFIED_BY="Clare Jess">
<P>An Ruifang (AR) and Xue Yan (XY) were co-authors of the original review. AR assisted with development of the original review. XY assisted with protocol development, searching for trials, quality assessment of trials, data extraction, data analysis and review development. We thank them for their contributions.</P>
<P>In addition, we thank Gail Quinn and Clare Jess (Managing Editors), and Jo Morrison and Chris Williams (Co-ordinating Editors), of the Cochrane Gynaecological Cancer Group (CGCG). We are most grateful to them all for their advice and support.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, funding to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-11-12 09:33:45 +0000" MODIFIED_BY="Gail Quinn">
<P>Deng Linyu (DLY): responsible for updating the review (2008). </P>
<P>Zhang Jing (ZJ): searching for trials, quality assessment of trials, data extraction, data analysis and review development. </P>
<P>Wu Taixiang (WT): protocol development, searching for trials, quality assessment of trials, data extraction, data analysis and review development and updating this version. </P>
<P>Tess Lawrie (TL) assisted with the writing of the updated 2012 review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Taixiang Wu">
<OL>
<LI>The 'Methods' section has been updated in accordance with the CGCG guidelines to include a revised 'Assessment of risk of bias of included studies', 'Measures of treatment effect' and 'Assessment of heterogeneity' section.</LI>
<LI>'Secondary cancers' has been added to the list of 'Secondary outcomes'.</LI>
<LI>The WHO ICTRP and its Primary Trial Registries have been added to the 'Search methods for identification of studies' section for ongoing studies.</LI>
<LI>The updated version of the review differs from the original review in that study data have been added to the analyses figures. However, meta-analyses could not be performed as only one study (<LINK REF="STD-Curry-1989" TYPE="STUDY">Curry 1989</LINK>) contributed data.</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-11-23 15:10:26 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Curry-1989" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Curry 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Curry SL, Blessing JA, Disaia PJ, Soper JT, Twiggs LB</AU>
<TI>A prospective randomised comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group Study</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>73</VL>
<NO>3 (part 1)</NO>
<PG>357-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-11-23 15:10:26 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-11-23 15:10:26 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alazzam-2012a" MODIFIED="2015-11-23 15:10:26 +0000" MODIFIED_BY="[Empty name]" NAME="Alazzam 2012a" TYPE="COCHRANE_REVIEW">
<AU>Alazzam M, Tidy J, Hancock BW, Osborne R, Lawrie T</AU>
<TI>First-line chemotherapy in low-risk gestational trophoblastic neoplasia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2012-10-29 22:57:43 +0000" MODIFIED_BY="Clare Jess">
<IDENTIFIER MODIFIED="2012-10-29 22:57:43 +0000" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD007102.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alazzam-2012b" MODIFIED="2015-11-23 15:09:11 +0000" MODIFIED_BY="[Empty name]" NAME="Alazzam 2012b" TYPE="COCHRANE_REVIEW">
<AU>Alazzam M, Tidy J, Osborne R, Coleman R, Hancock B, Lawrie TA</AU>
<TI>Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-11-23 15:08:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-23 15:08:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008891.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bagshawe-1976" NAME="Bagshawe 1976" TYPE="JOURNAL_ARTICLE">
<AU>Bagshawe KD</AU>
<TI>Risk and prognostic factors in trophoblastic neoplasia</TI>
<SO>Cancer</SO>
<YR>1976</YR>
<VL>38</VL>
<PG>1373-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagshawe-1977" NAME="Bagshawe 1977" TYPE="JOURNAL_ARTICLE">
<AU>Bagshawe KD</AU>
<TI>Treatment of trophoblastic tumours</TI>
<SO>Recent Results Cancer Research</SO>
<YR>1977</YR>
<VL>62</VL>
<PG>192-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagshawe-1986" MODIFIED="2012-11-14 16:55:26 +0000" MODIFIED_BY="Anne Lawson" NAME="Bagshawe 1986" TYPE="JOURNAL_ARTICLE">
<AU>Bagshawe KD, Dent J, Webb J</AU>
<TI>Hydatidiform mole in England and Wales, 1973-1983</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>ii</VL>
<PG>673</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bianconi-2012" MODIFIED="2012-10-19 13:27:52 +0100" MODIFIED_BY="[Empty name]" NAME="Bianconi 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bianconi MI, Otero S, Moscheni O, Alvarez L, Storino C, Jankilevich G</AU>
<TI>Gestational trophoblastic disease: a 21-year review of the clinical experience at an Argentinean public hospital</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>7-8</NO>
<PG>341-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bolis-1988" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Bolis 1988" TYPE="JOURNAL_ARTICLE">
<AU>Bolis G, Bonazzi C, Landoni F, Mangili G, Vergadoro F, Zanaboni F, et al</AU>
<TI>EMA/CO regimen in high-risk gestational trophoblastic tumour</TI>
<SO>Gynecologic Oncology</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>439-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bower-1997" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="Gail Quinn" NAME="Bower 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al</AU>
<TI>EMA-CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>2639</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cagayan-2012" MODIFIED="2012-10-19 13:27:59 +0100" MODIFIED_BY="[Empty name]" NAME="Cagayan 2012" TYPE="JOURNAL_ARTICLE">
<AU>Cagayan MS</AU>
<TI>High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>5-6</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chauhan-2010" MODIFIED="2012-10-19 13:28:06 +0100" MODIFIED_BY="[Empty name]" NAME="Chauhan 2010" TYPE="JOURNAL_ARTICLE">
<AU>Chauhan A, Dave K, Desai A, Mankad M, Patel S, Dave P</AU>
<TI>High-risk gestational trophoblastic neoplasia at Gujarat Cancer and Research Institute: thirteen years of experience</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>7-8</NO>
<PG>333-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTCAE-2010" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="CTCAE 2010" TYPE="OTHER">
<AU>National Cancer Institute</AU>
<TI>Common Terminology Criteria for Adverse Events (CTCAE), v 4.0, June 2010. evs.nci.nih.gov/ftp1/CTCAE/About.html</TI>
<SO>(accessed 12 November 2012)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cyriac-2011a" MODIFIED="2012-10-19 13:28:12 +0100" MODIFIED_BY="[Empty name]" NAME="Cyriac 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Cyriac S, Rajendranath R, Sridevi V, Sagar TG</AU>
<TI>Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2011</YR>
<VL>56</VL>
<NO>6</NO>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cyriac-2011b" MODIFIED="2012-10-02 11:23:53 +0100" MODIFIED_BY="[Empty name]" NAME="Cyriac 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Cyriac S, Rajendranath R, Sridevi V, Sagar TG</AU>
<TI>Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>2011</YR>
<VL>115</VL>
<NO>1</NO>
<PG>37-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Decherney-2003" NAME="Decherney 2003" TYPE="BOOK">
<AU>Decherney AH, Nathan L</AU>
<SO>The care and treatment of women</SO>
<YR>2003</YR>
<PB>Ren-ming Wei-sheng Chu-banshe</PB>
<CY>China</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<PG>285-312</PG>
<EN>2nd</EN>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publication Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2012-10-19 13:28:25 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dobson-2000" MODIFIED="2012-10-01 09:18:43 +0100" MODIFIED_BY="[Empty name]" NAME="Dobson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Dobson LS, Lorigan PC, Coleman RE, Hancock BW</AU>
<TI>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease</TI>
<SO>British Journal of Cancer</SO>
<YR>2000</YR>
<VL>82</VL>
<PG>1547-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Driscoll-1981" NAME="Driscoll 1981" TYPE="JOURNAL_ARTICLE">
<AU>Driscoll SG</AU>
<TI>Trophoblastic growths: morphologic aspects and taxonomy</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1981</YR>
<VL>26</VL>
<PG>2181</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Escobar-2003" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Escobar 2003" TYPE="JOURNAL_ARTICLE">
<AU>Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA</AU>
<TI>Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine chemotherapy</TI>
<SO>Gynecological Oncology</SO>
<YR>2003</YR>
<VL>91</VL>
<PG>552-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ezoe-2012" MODIFIED="2012-10-19 13:28:39 +0100" MODIFIED_BY="[Empty name]" NAME="Ezoe 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ezoe S</AU>
<TI>Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor</TI>
<SO>International Journal of Environmental Research and Public Health</SO>
<YR>2012</YR>
<VL>9</VL>
<PG>2444-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feng-2011" MODIFIED="2012-09-28 13:59:41 +0100" MODIFIED_BY="[Empty name]" NAME="Feng 2011" TYPE="JOURNAL_ARTICLE">
<AU>Feng F, Xiang Y, Wan X, Geng S, Wang T</AU>
<TI>Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia</TI>
<SO>Annals of Oncology</SO>
<YR>2011</YR>
<VL>22</VL>
<PG>1588-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FIGO-2009" MODIFIED="2012-09-27 12:40:57 +0100" MODIFIED_BY="[Empty name]" NAME="FIGO 2009" TYPE="JOURNAL_ARTICLE">
<AU>FIGO Committee on Gynecologic Oncology</AU>
<TI>Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>2009</YR>
<VL>105</VL>
<PG>3-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-2009" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Fisher 2009" TYPE="BOOK_SECTION">
<AU>Fisher R</AU>
<TI>Genetics</TI>
<SO>Gestational Trophoblastic Disease. www.isstd.org/isstd/book.html</SO>
<YR>2009</YR>
<PG>6-48</PG>
<EN>3rd</EN>
<ED>Hancock BW, Seckl M, Berkowitz RS, Cole LA</ED>
<PB>International Society for the Study of Trophoblastic Diseases</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-F_x00fc_l_x00f6_p-2012" MODIFIED="2012-10-19 13:28:46 +0100" MODIFIED_BY="[Empty name]" NAME="Fülöp 2012" TYPE="JOURNAL_ARTICLE">
<AU>Fülöp V, Szigetvári I, Szepesi J, Végh G, Singh M, Berkowitz RS</AU>
<TI>Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>7-8</NO>
<PG>310-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghaemmaghami-2004" MODIFIED="2012-09-28 13:47:15 +0100" MODIFIED_BY="[Empty name]" NAME="Ghaemmaghami 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ghaemmaghami F, Modares M, Arab M, Behtash N, Moosavi AZ, Khanafshar N, et al</AU>
<TI>EMA-EP regimen, as first line multiple agent chemotherapy in high-risk GTT patients (stage II-IV)</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>2</NO>
<PG>360-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-2012" MODIFIED="2012-10-19 13:28:54 +0100" MODIFIED_BY="[Empty name]" NAME="Goldstein 2012" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein DP, Berkowitz RS</AU>
<TI>Current management of gestational trophoblastic neoplasia</TI>
<SO>Hematology Oncology Clinics of North America</SO>
<YR>2012</YR>
<VL>26</VL>
<PG>111-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hammond-1973" NAME="Hammond 1973" TYPE="JOURNAL_ARTICLE">
<AU>Hammond CB, Borchert LG, Tyrey L, Creasman WT, Parker RT</AU>
<TI>Treatment of metastatic trophoblastic disease: good and poor prognosis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1973</YR>
<VL>115</VL>
<PG>451-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harma-2005" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="Anne Lawson" NAME="Harma 2005" TYPE="JOURNAL_ARTICLE">
<AU>Harma M, Harma M, Yurtseven S, Gungen N</AU>
<TI>Gestational trophoblastic disease in Sanliurfa, southeast Anatolia, Turkey</TI>
<SO>European Journal of Gynaecologic Oncology</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>3</NO>
<PG>306-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayashi-1982" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="Anne Lawson" NAME="Hayashi 1982" TYPE="JOURNAL_ARTICLE">
<AU>Hayashi K, Bracken MB, Freeman DH, Hellenbrand K</AU>
<TI>Hydatidiform mole in the United States (1970-1977): a statistical and theoretical analysis</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1982</YR>
<VL>115</VL>
<PG>67-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-10-19 13:29:02 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH-1997" NAME="ICH 1997" TYPE="CONFERENCE_PROC">
<AU>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)</AU>
<TI>Good clinical practice consolidated guideline</TI>
<SO>Federal Register</SO>
<YR>1997;62</YR>
<NO>90</NO>
<PG>25691-709</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-1998" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kim SJ, Bae SN, Kim JH, Kim CT, Han KT, Lee JM, et al</AU>
<TI>Effects of multi agent chemotherapy and independent risk factors in the treatment of high-risk GTT - 25 years experience of KRI-TRD</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>1998</YR>
<VL>60 Suppl 1</VL>
<PG>85-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohorn-2001" MODIFIED="2012-09-26 11:39:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kohorn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kohorn EI</AU>
<TI>The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment</TI>
<SO>International Journal of Gynecologic Cancer</SO>
<YR>2001</YR>
<VL>11</VL>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurman-1984" NAME="Kurman 1984" TYPE="JOURNAL_ARTICLE">
<AU>Kurman RJ, Main CS, Chen HC</AU>
<TI>Intermediate trophoblast: a distinctive form of trophoblast with specific morphological, biochemical, and functional features</TI>
<SO>Placenta</SO>
<YR>1984</YR>
<VL>5</VL>
<PG>349-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2009" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 2009" TYPE="BOOK_SECTION">
<AU>Lee C, Smith HO, Kim SJ</AU>
<TI>Epidemiology</TI>
<SO>Gestational Trophoblastic Diseases. www.isstd.org/isstd/book.html</SO>
<YR>2009</YR>
<PG>49-96</PG>
<EN>3rd</EN>
<ED>Hancock BW, Newlands ES, Berkowitz RS, Cole LA</ED>
<PB>International Society for the Study of Trophoblastic Diseases</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2008" MODIFIED="2012-10-19 13:29:10 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lu WG, Ye F, Shen YM, Fu YF, Chen HZ, Wan XY, et al</AU>
<TI>EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>2</NO>
<PG>357-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lurain-1982" NAME="Lurain 1982" TYPE="JOURNAL_ARTICLE">
<AU>Lurain JR, Brewer JI</AU>
<TI>Invasive mole</TI>
<SO>Seminars Oncology</SO>
<YR>1982</YR>
<VL>9</VL>
<PG>174-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lurain-2010" MODIFIED="2012-10-19 13:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="Lurain 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lurain JR, Singh DK, Schink JC</AU>
<TI>Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score &gt; or = 7</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>5-6</NO>
<PG>199-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lurain-2011" MODIFIED="2012-10-04 11:22:46 +0100" MODIFIED_BY="[Empty name]" NAME="Lurain 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lurain JR</AU>
<TI>Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>2011</YR>
<VL>January</VL>
<PG>11-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matsui-2000" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Matsui 2000" TYPE="JOURNAL_ARTICLE">
<AU>Matsui H, Suzuka K, Iitsuka Y, Seki K, Sekiya S</AU>
<TI>Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors</TI>
<SO>Gynecologic Oncology</SO>
<YR>2000</YR>
<VL>78</VL>
<NO>1</NO>
<PG>28-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazur-1987" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="Anne Lawson" NAME="Mazur 1987" TYPE="CONFERENCE_PROC">
<AU>Mazur MT, Szulman AE, Buchsbaum HJ (editors)</AU>
<TI>Choriocarcinoma and placental site trophoblastic tumour (in gestational trophoblastic disease)</TI>
<SO>New York Springer-Verlag</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newlands-1986" NAME="Newlands 1986" TYPE="JOURNAL_ARTICLE">
<AU>Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L, Dent J</AU>
<TI>Developments in chemotherapy for medium and high risk patients with gestational trophoblastic tumours (1979-1984)</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1986</YR>
<VL>93</VL>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newlands-1998" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="Anne Lawson" NAME="Newlands 1998" TYPE="JOURNAL_ARTICLE">
<AU>Newlands ES, Bower M, Holden L, Short D, Seckl MJ, Rustin GJ, et al</AU>
<TI>Management of resistant gestational trophoblastic tumors</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>2</NO>
<PG>111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newlands-2000" MODIFIED="2012-10-05 11:02:16 +0100" MODIFIED_BY="[Empty name]" NAME="Newlands 2000" TYPE="JOURNAL_ARTICLE">
<AU>Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ</AU>
<TI>Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>854-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pastorfide-1974" NAME="Pastorfide 1974" TYPE="JOURNAL_ARTICLE">
<AU>Pastorfide GB, Goldstein DP, Kosasa TS</AU>
<TI>The use of a radioimmunoassay specific for human chorionic gonadotropin in patients with molar pregnancy and gestational trophoblastic disease</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1974</YR>
<VL>120</VL>
<PG>1025-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Popiolek-2006" MODIFIED="2012-10-19 13:29:23 +0100" MODIFIED_BY="[Empty name]" NAME="Popiolek 2006" TYPE="JOURNAL_ARTICLE">
<AU>Popiolek DA, Yee H, Mittal K, Chiriboga L, Prinz MK, Caragine TA, et al</AU>
<TI>Multiplex short tandem repeat DNA analysis confirms the accuracy of p57(KIP2) immunostaining in the diagnosis of complete hydatidiform mole</TI>
<SO>Human Pathology</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>11</NO>
<PG>1426-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schink-1992" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Schink 1992" TYPE="JOURNAL_ARTICLE">
<AU>Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR</AU>
<TI>Etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1992</YR>
<VL>80</VL>
<PG>817-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schorge-2003" NAME="Schorge 2003" TYPE="BOOK">
<AU>Schorge JO</AU>
<SO>Contemporary therapy in obstetrics and gynecology</SO>
<YR>2003</YR>
<PB>Ren-ming Wei-sheng Chu-banshe</PB>
<CY>China</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seckl-2009a" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Seckl 2009a" TYPE="BOOK_SECTION">
<AU>Seckl MJ</AU>
<TI>Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours (GTT) in the United Kingdom</TI>
<SO>Gestational trophoblastic disease. www.isstd.org/isstd/book.html</SO>
<YR>2009</YR>
<PG>277-298</PG>
<EN>3rd</EN>
<ED>Hancock BW, Seckl MJ, Berkowitz RS, Cole LA</ED>
<PB>International Society for the Study of Trophoblastic Diseases</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seckl-2009b" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NAME="Seckl 2009b" TYPE="BOOK_SECTION">
<AU>Seckl MJ</AU>
<TI>Investigation and treatment of patients with persistent gestational trophoblastic disease and gestational trophoblastic tumours/neoplasia in the United Kingdom</TI>
<SO>Gestational Trophoblastic Disease. www.isstd.org/isstd/book.html</SO>
<YR>2009</YR>
<PG>335-66</PG>
<EN>3rd</EN>
<ED>Hancock BW, Seckl MJ, Berkowitz RS, Cole LA</ED>
<PB>International Society for the Study of Trophoblastic Diseases</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seckl-2010" MODIFIED="2012-09-27 11:31:13 +0100" MODIFIED_BY="[Empty name]" NAME="Seckl 2010" TYPE="JOURNAL_ARTICLE">
<AU>Seckl MJ, Sebire NJ, Berkowitz RS</AU>
<TI>Gestational trophoblastic disease</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<PG>717-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-2004" NAME="Song 2004" TYPE="BOOK">
<AU>Song HZ</AU>
<SO>Diagnosis and treatment of trophoblastic tumours</SO>
<YR>2004</YR>
<PB>Ren-ming Wei-sheng Chu-banshe</PB>
<CY>China</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soper-1994" MODIFIED="2012-10-19 12:31:07 +0100" MODIFIED_BY="[Empty name]" NAME="Soper 1994" TYPE="JOURNAL_ARTICLE">
<AU>Soper JT, Evans AC, Clark-Pearson DL, Berchuck A, Rodriguez G, Hammond CB</AU>
<TI>Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1994</YR>
<VL>83</VL>
<NO>1</NO>
<PG>113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Szulman-1978" NAME="Szulman 1978" TYPE="JOURNAL_ARTICLE">
<AU>Szulman AE, Surti U</AU>
<TI>The syndromes of hydatidiform mole: I. cytogenic and morphologic correlations and II morphologic evolution of the complete and partial mole</TI>
<SO>American Journal Obstetrics and Gynecology</SO>
<YR>1978</YR>
<VL>131 and 132</VL>
<PG>665-71;20-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2003" NAME="Tang 2003" TYPE="BOOK">
<AU>Tang Zhao-you</AU>
<SO>Current Tumourology</SO>
<YR>2003</YR>
<PB>Ren-ming Wei-sheng Chu-banshe</PB>
<CY>China</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turan-2006" MODIFIED="2012-10-19 13:29:53 +0100" MODIFIED_BY="[Empty name]" NAME="Turan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Turan T, Karacay O, Tulunay G Boran N, Koc S, Bozok S, et al</AU>
<TI>Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>1432-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2006" MODIFIED="2012-09-28 13:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wang S, An R, Han X, Zhu K, Xue Y</AU>
<TI>Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences</TI>
<SO>Gynecologic Oncology</SO>
<YR>2006</YR>
<VL>103</VL>
<NO>3</NO>
<PG>1105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1983" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="Anne Lawson" NAME="WHO 1983" TYPE="CONFERENCE_PROC">
<AU>WHO Scientific Group</AU>
<TI>Gestational trophoblastic disease</TI>
<SO>Technical Report Series No 692</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-1986" NAME="Wong 1986" TYPE="JOURNAL_ARTICLE">
<AU>Wong LC, Choo YC, Ma HK</AU>
<TI>Modified Bagshawe's regimen in high-risk gestational trophoblastic disease</TI>
<SO>Gynecologic Oncology</SO>
<YR>1986</YR>
<VL>23</VL>
<PG>87-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhao-2000" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="Taixiang Wu" NAME="Zhao 2000" TYPE="JOURNAL_ARTICLE">
<AU>Zhao Xia-yu</AU>
<TI>Gestational trophoblastic tumours with EMA/CP regime: an analysis of 22 cases</TI>
<SO>Journal of Bengbu Medical School</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>5</NO>
<PG>334-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhao-2009" MODIFIED="2012-09-28 13:58:49 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2009" TYPE="JOURNAL_ARTICLE">
<AU>Zhao Y, Zhang W, Duan W</AU>
<TI>Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>2</NO>
<PG>88-94</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-10-29 23:08:26 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Deng-2009" MODIFIED="2012-10-29 23:08:26 +0000" MODIFIED_BY="[Empty name]" NAME="Deng 2009" TYPE="COCHRANE_REVIEW">
<AU>Deng L, Yan X, Zhang J, Wu T</AU>
<TI>Combination chemotherapy for high-risk gestational trophoblastic tumour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-10-29 23:08:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-29 23:08:26 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005196.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Taixiang Wu">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Taixiang Wu" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Taixiang Wu" STUDY_ID="STD-Curry-1989">
<CHAR_METHODS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Taixiang Wu">
<P>Multicentre RCT conducted in the US from 1981 to 1986 by the Gynecologic Oncology Group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>42 women with metastatic GTN with at least 1 high-risk factor including: duration of disease &gt; 4 months; brain or liver metastases; hCG &gt; 42,000 mIU/mL; failed previous chemotherapy; and post-term pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1 (22 participants): methotrexate, actinomycin D, chlorambucil (MAC) regimen, repeated every 21 days (12- to 14-day window)<BR/>Group 2 (20 participants): cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, doxorubicin, melphalan, vincristine (CHAMOMA) regimen, repeated every 21 days (10- to 14-day window).<BR/>Patients with cerebral or liver metastases also received radiation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>Death: 4% (1/22) with MAC vs. 30% (6/20)with CHAMOMA</P>
<P>Response to therapy with primary treatment: 73% (16/22) with MAC vs. 65% (13/20) with CHAMOMA</P>
<P>Response to therapy with secondary treatment: 23% (5/220) with MAC vs. 5% (91/20) with CHAMOMA<BR/>Haematological toxicity: 36% (8/22) with MAC vs. 85% (17/20) with CHAMOMA<BR/>Total toxicity: 50% (11/22) with MAC vs. 90% (18/20) with CHAMOMA<BR/>Life-threatening haematological toxicity: 9% (2/22) with MAC vs. 40% (8/20) with CHAMOMA</P>
<P>Life-threatening total toxicity: 9% (2/22) with MAC vs. 45% (9/20) with CHAMOMA</P>
<P>Treatment was considered to have failed if there was a hCG plateau over 3 weeks, a rise of &gt; 20% over 2 weeks, or if new metastases occurred. The treatment was then discontinued and patients received other chemotherapy or operative procedures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>Baseline risk characteristics were similar between the 2 groups but mean age was not reported</P>
<P>Investigators had intended to enrol 40 patients to each arm but the trial was stopped early because the CHAMOMA regimen was considered "significantly more toxic and possibly less effective"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>GTN: gestational trophoblastic disease; hCG: human chorionic gonadotrophin; RCT: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curry-1989">
<DESCRIPTION>
<P>Randomisation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curry-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curry-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curry-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Curry-1989">
<DESCRIPTION>
<P>No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curry-1989">
<DESCRIPTION>
<P>Pre-specified outcomes (toxicity and effectiveness) were reported. Mean age was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Curry-1989">
<DESCRIPTION>
<P>No other risks noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-10-05 08:01:27 +0100" MODIFIED_BY="[Empty name]">Modified WHO Prognostic Scoring System for GTN as adapted by FIGO</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TD>
<P>Scores</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>Age (years)</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 40</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8805;40</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8211;</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8211;</P>
</TD>
</TR>
<TR>
<TD>
<P>Antecedent pregnancy</P>
</TD>
<TD ALIGN="CENTER">
<P>mole</P>
</TD>
<TD ALIGN="CENTER">
<P>abortion</P>
</TD>
<TD ALIGN="CENTER">
<P>term</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8211;</P>
</TD>
</TR>
<TR>
<TD>
<P>Interval months from index pregnancy</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 4</P>
</TD>
<TD ALIGN="CENTER">
<P>4 to 6</P>
</TD>
<TD ALIGN="CENTER">
<P>7 to 12</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 12</P>
</TD>
</TR>
<TR>
<TD>
<P>Pre-treatment serum hCG (IU/L)</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 10<SUP>3 </SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10<SUP>3 </SUP>to 10<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10<SUP>4</SUP> to 10<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 10<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Largest tumour size (including uterus) (cm)</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 3</P>
</TD>
<TD ALIGN="CENTER">
<P>3 to 4</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8805; 5</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8211;</P>
</TD>
</TR>
<TR>
<TD>
<P>Site of metastases</P>
</TD>
<TD ALIGN="CENTER">
<P>lung</P>
</TD>
<TD ALIGN="CENTER">
<P>spleen, kidney</P>
</TD>
<TD ALIGN="CENTER">
<P>gastrointestinal</P>
</TD>
<TD ALIGN="CENTER">
<P>liver, brain</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of metastases</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8211;</P>
</TD>
<TD ALIGN="CENTER">
<P>1 to 4</P>
</TD>
<TD ALIGN="CENTER">
<P>5 to 8</P>
</TD>
<TD ALIGN="CENTER">
<P>&gt; 8</P>
</TD>
</TR>
<TR>
<TD>
<P>Previous failed chemotherapy</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8211;</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8211;</P>
</TD>
<TD ALIGN="CENTER">
<P>single drug</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8805; 2 drugs</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<I>To stage and allot a risk factor score, a patient's diagnosis is allocated to a stage as represented by a Roman numeral I, II, III, and IV. This is then separated by a colon from the sum of all the actual risk factor scores expressed in Arabic numerals, i.e. stage II:4, stage IV:9. This stage and score will be allotted for each patient (</I>
<LINK REF="REF-FIGO-2009" TYPE="REFERENCE">FIGO 2009</LINK>). <I>A score &#8804; 6 indicates low-risk; &gt; 6 indicates high-risk.</I>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-09-27 12:40:14 +0100" MODIFIED_BY="[Empty name]">FIGO anatomical staging *</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TD>
<P>Stage I</P>
</TD>
<TD ALIGN="LEFT">
<P>Disease confined to the uterus</P>
</TD>
</TR>
<TR>
<TD>
<P>Stage II</P>
</TD>
<TD>
<P>GTN extends outside of the uterus, but is limited to the genital structures (adnexa, vagina, broad ligament)</P>
</TD>
</TR>
<TR>
<TD>
<P>Stage III</P>
</TD>
<TD>
<P>GTN extends to the lungs with or without known genital tract involvement</P>
</TD>
</TR>
<TR>
<TD>
<P>Stage IV</P>
</TD>
<TD>
<P>All other metastatic sites</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*From <LINK REF="REF-FIGO-2009" TYPE="REFERENCE">FIGO 2009</LINK>.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-10-19 11:23:46 +0100" MODIFIED_BY="[Empty name]">EMA-CO chemotherapy regimen *</TITLE>
<TABLE COLS="2" ROWS="13">
<TR>
<TD COLSPAN="2">
<P>Schedule</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Day 1 (EMA)</P>
</TD>
</TR>
<TR>
<TD>
<P>Etoposide</P>
</TD>
<TD>
<P>100 mg/m<SUP>2</SUP> by intravenous infusion for 30 min</P>
</TD>
</TR>
<TR>
<TD>
<P>Actinomycin D</P>
</TD>
<TD>
<P>0·5 mg intravenous bolus</P>
</TD>
</TR>
<TR>
<TD>
<P>Methotrexate</P>
</TD>
<TD>
<P>300 mg/m<SUP>2</SUP> by intravenous infusion for 12 h<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Day 2</P>
</TD>
</TR>
<TR>
<TD>
<P>Etoposide</P>
</TD>
<TD>
<P>100 mg/m<SUP>2</SUP> by intravenous infusion for 30 min</P>
</TD>
</TR>
<TR>
<TD>
<P>Actinomycin D</P>
</TD>
<TD>
<P>0·5 mg intravenous bolus</P>
</TD>
</TR>
<TR>
<TD>
<P>Folinic acid rescue&#8224;</P>
</TD>
<TD>
<P>15 mg intramuscularly or orally every 12 h for 4 doses</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>Day 8 (CO)</P>
</TD>
</TR>
<TR>
<TD>
<P>Vincristine</P>
</TD>
<TD>
<P>1 mg/m<SUP>2</SUP> intravenous bolus (maximum 2 mg)</P>
</TD>
</TR>
<TR>
<TD>
<P>Cyclophosphamide</P>
</TD>
<TD>
<P>600 mg/m<SUP>2</SUP> intravenous infusion for 30 min</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>EMA alternates with CO every week.</P>
<P>&#8224;Rescue begun 24 h after start of methotrexate infusion.</P>
<P>The problem of myelosuppression is usually overcome by administering G-CSF (e.g. filgrastim) and increasing the frequency (4 doses daily) and duration (up to 4 days) of folinic acid rescue.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*From <LINK REF="REF-Seckl-2010" TYPE="REFERENCE">Seckl 2010</LINK>.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-11-14 16:54:27 +0000" MODIFIED_BY="[Empty name]">Cohort studies of EMA-CO for primary treatment of high-risk GTN</TITLE>
<TABLE COLS="8" ROWS="16">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Study ID</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Study period</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Country</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Participants with high-risk GTN</P>
<P>undergoing primary treatment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>CT regimen</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Primary remission rate</P>
<P>(CR)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Median follow-up</P>
<P>(months)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>OS</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="REF-Bolis-1988" TYPE="REFERENCE">Bolis 1988</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1980 to 1985</P>
</TD>
<TD ALIGN="CENTER">
<P>Italy</P>
</TD>
<TD ALIGN="CENTER">
<P>22</P>
</TD>
<TD ALIGN="CENTER">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER">
<P>94%</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER">
<P>88%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="REF-Soper-1994" TYPE="REFERENCE">Soper 1994</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1966 to 1992</P>
</TD>
<TD ALIGN="CENTER">
<P>North America</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER">
<P>67%</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<LINK REF="REF-Schink-1992" TYPE="REFERENCE">Schink 1992</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1986 to 1991</P>
</TD>
<TD ALIGN="CENTER">
<P>North America</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER">
<P>83%</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>100%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Newlands-1998" TYPE="REFERENCE">Newlands 1998</LINK>; <LINK REF="REF-Bower-1997" TYPE="REFERENCE">Bower 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1979 to 1995</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>272 ¹</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>78%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>87%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Kim-1998" TYPE="REFERENCE">Kim 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1971 to 1995</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Korea</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>227 ²</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO (96); MA (49); MAC (40);</P>
<P>CHAMOCA (42)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO: 91%; MA: 63%; MAC: 68%; CHAMOCA: 76%</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>All follow-up exceeded 24 months</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-Escobar-2003" TYPE="REFERENCE">Escobar 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1986 to 2001</P>
</TD>
<TD ALIGN="CENTER">
<P>North America</P>
</TD>
<TD ALIGN="CENTER">
<P>25</P>
</TD>
<TD ALIGN="CENTER">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER">
<P>76%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="CENTER">
<P>92%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Turan-2006" TYPE="REFERENCE">Turan 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1994 to 2004</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Turkey</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>53</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>91%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Lu-2008" TYPE="REFERENCE">Lu 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1996 to 2005</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>China</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>45</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>78%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>56 &#8308;</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>93%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Lurain-2010" TYPE="REFERENCE">Lurain 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1989 to 2009</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>North America</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>62%&#8311;</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>92%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Chauhan-2010" TYPE="REFERENCE">Chauhan 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1995 to 2008</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>India</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>67³</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>75% (43/57)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>range, 12 to 72</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>93%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-Cyriac-2011a" TYPE="REFERENCE">Cyriac 2011a</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1997 to 2006</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>India</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>29</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>76%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>47</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>71%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Bianconi-2012" TYPE="REFERENCE">Bianconi 2012</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1990 to 2011</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Argentina</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO (for scores 7 to 13);</P>
<P>EMA/EP for scores &gt; 13</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>83%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>93%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Cagayan-2012" TYPE="REFERENCE">Cagayan 2012</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2006 to 2010</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Phillipines</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>67</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO &#8309;</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>71%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>86%</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-F_x00fc_l_x00f6_p-2012" TYPE="REFERENCE">Fülöp 2012</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1977- to 2010</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Hungary</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>174</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO (26); MAC (118);</P>
<P>BEP (17) &#8310;</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>EMA/CO: 81%; MAC: 93%</P>
<P>BEP: 94%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>97%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="8">
<P>CT: chemotherapy; CR: complete response; OS: overall survival; EMA/CO: etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine; EMA/EP: etoposide, methotrexate, actinomycin D/etoposide, cisplatin; MAC: methotrexate, actinomycin D, cyclophosphamide or chlorambucil; BEP: bleomycin, etoposide, cisplatin.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>¹ This study included 121 women undergoing secondary/salvage treatment.</P>
<P>² MA and MAC were used mainly between 1971 and 1982; CHAMOCA was used between 1982 and 1985; EMA/CO was used from 1985 to 1995. Mean age and prognostic scores were similar in these groups.</P>
<P>³ Only 57 were treated with EMA/CO, the other 10 were treated with EMA.</P>
<P>&#8308; Mean not median.</P>
<P>&#8309; 56 women completed treatment.</P>
<P>&#8310; Prognostic scores differed between these treatment groups as follows: MAC = 11.5, EMA/CO = 13.2 and BEP = 15.5.</P>
<P>&#8311; Two patients relapsed from remission at 4 and 5 months therefore the overall durable CR was 54%.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-11-12 11:03:00 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-11-12 11:03:00 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Modified CHAMOMA versus MAC</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-12 11:02:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>CHAMOMA</GROUP_LABEL_1>
<GROUP_LABEL_2>MAC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CHAMOMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAC</GRAPH_LABEL_2>
<DICH_DATA CI_END="50.18018254878097" CI_START="0.8680717723108042" EFFECT_SIZE="6.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7005322368866038" LOG_CI_START="-0.06144436580286664" LOG_EFFECT_SIZE="0.8195439355418687" MODIFIED="2012-09-26 11:06:56 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="1.0349937783446437" STUDY_ID="STD-Curry-1989" TOTAL_1="20" TOTAL_2="22" VAR="1.0712121212121213" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-12 11:02:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Response to treatment</NAME>
<GROUP_LABEL_1>CHAMOMA</GROUP_LABEL_1>
<GROUP_LABEL_2>MAC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHAMOMA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-26 11:34:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Remission with primary treatment</NAME>
<DICH_DATA CI_END="1.348036764272124" CI_START="0.5925573275676264" EFFECT_SIZE="0.89375" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.1297017366375722" LOG_CI_START="-0.2272696270192981" LOG_EFFECT_SIZE="-0.04878394519086295" MODIFIED="2012-09-26 11:01:03 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.20968674604879411" STUDY_ID="STD-Curry-1989" TOTAL_1="20" TOTAL_2="22" VAR="0.04396853146853147" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-26 11:34:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Remission with secondary treatment</NAME>
<DICH_DATA CI_END="1.7258895907310379" CI_START="0.028043508843169477" EFFECT_SIZE="0.22" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23701300941512893" LOG_CI_START="-1.5521676477707165" LOG_EFFECT_SIZE="-0.6575773191777937" MODIFIED="2012-09-26 11:04:28 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="1.050973574618056" STUDY_ID="STD-Curry-1989" TOTAL_1="20" TOTAL_2="22" VAR="1.1045454545454545" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-12 11:03:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Total toxicity (grade 3/4)</NAME>
<GROUP_LABEL_1>CHAMOMA</GROUP_LABEL_1>
<GROUP_LABEL_2>MAC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CHAMOMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAC</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8023341131175674" CI_START="1.15617905260966" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.4475199135453449" LOG_CI_START="0.06302509666126735" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2012-09-26 11:36:32 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.22585415871774644" STUDY_ID="STD-Curry-1989" TOTAL_1="20" TOTAL_2="22" VAR="0.051010101010101006" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-26 12:05:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Haematological toxicity (grade 3/4)</NAME>
<GROUP_LABEL_1>CHAMOMA</GROUP_LABEL_1>
<GROUP_LABEL_2>MAC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CHAMOMA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MAC</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.185888260070846" CI_START="1.3053158399186517" EFFECT_SIZE="2.3375" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.6217876309108501" LOG_CI_START="0.11571560817826067" LOG_EFFECT_SIZE="0.3687516195445554" MODIFIED="2012-09-26 11:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.29726921125003725" STUDY_ID="STD-Curry-1989" TOTAL_1="20" TOTAL_2="22" VAR="0.08836898395721927" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-11-23 14:57:51 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram of updated search (12 September 2012).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUEAAAG/CAYAAADGlmVYAAAic0lEQVR42u2df2RW7//HI0mSROZt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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-11-23 14:57:51 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram of update search (May 2015)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAI0CAYAAAA3L6+UAAAylklEQVR42u3dD6RVadvA/4ckyUgk
jySJJEkSychIIkker8TII+P1GpKMjMQrSZJIkiRDkkcyYmQkSSR5JSNGkiSRJEkiYyTJ+rnW77fO
b53V3utea+9zTvuc/fmydfaftdZ9r3Vd93f9a13/yEr84x//8Bqi16Bhm4g/TE7+UU5iDNnGH6Bt
Lv7EHya5SGxQyWxAgW2PPrajDSkI/jGUy4b4A5GASCD+QCQgEvEn/sQAkUAiG0QgBogEEtkgAjEA
IgGRQPyBSEAkU4WHDx8KLCIhkuDSpUvZokWLshkzZmRr1qzJHjx40Or74MOHD9mSJUv6bui1a9ey
6dOnZ6tWrZIkQyCS+Dzi62u3NbW88vflvyMnvla7J9vATCRTWCR//PFHtnbt2uz58+fZ58+fs4sX
L2bLli1r/H3w6dOnbNu2bWMSKCGR69ev29saIpGsXr063xGZLCJxlEckRFJhx44d2fHjx7tOmPo+
WL9+ffbixYvGgbJ///5s1qxZ2cyZM/NpX758ORJoqWf0xOf37t3L5s2blw9ABYcPH85mz56dz3fv
3r2jpvn48WO2c+fOfHlLly7N7t6926g93ZYXQt29e3f2zTffZPPnz8/3qMvtLY6qpk2blq1YsSK7
ffs2kdRsz19++SU7dOhQ7e/rtlGVZ8+eZVu3bs1/G9shtvmVK1dGvk9tv9T3xd+d4rVNu+O358+f
zxYuXJjHSnUnKtUPIsHAiCSCuO48b+r74ObNm40D5cSJE9np06fzZI3X2bNn80G+zZ7hnj178mlf
vXqVfxbziISMz+LoKBL/2LFjI9McPHgwu3z5cv731atXRx1RNWlPdXknT57Mjh49mn/25s2bbN26
daPaXR4Qbty4kS1evJhIEnv0ccq0Osg23UZVVq5cmR85F7+PaWNHoCC1/VLfd/u7bbvjtyGKot8R
MxE7TftBJBgYkUTgxmAXezux57N9+/bs3bt3jb9vGyjLly/PjxDKRwtz585tJZLq3mhcT4lEK1Me
vEMc1e/btKe6vDgyKU9z//79Ue2OZC/EJZGbieTOnTvZ999/3/H3qW3UhNjjb7r9Ut83FUkvsZXa
RuV+EAkGRiTx+a5du7L379+P7DXF6aym37cNlHIilGXVRiSdpq+eZigvpzz/sWhPdX6xXsq/C/HG
+xBc9ZQNkXT/PEQSQql+ntpGnYjTkXEkGrEaA3r1iLFu+6W+byqSXmKr+lldP4gEAyOSOA9c3muK
pCnfiZL6vm2gdBoA2iRHp+87JWzTQaeX9qSmKQaAOI22adOmbN++fUTSQCRxnS1OcVU/b7K+y1y4
cCE/Cj137lx+2jVOSbaZX5uYqBNJL7FV/izVDyLBwIhk8+bNX+x9xSmspt+3DZS4+Fw93C+LqReR
xDzjiKkbcVtyt1NbvbQn7mIrT/Po0aOu7Y5bpQclgQZdJEEcwcXF9/LnqW3UaeeoHA9xx2F5fqnt
l/q+qUh6ia3yZ6l+EAkGRiRxLj9exQW9U6dOjewVNvm+baDEBciYRzG/M2fOjPr/J72IJOZZXByN
V7yPO2QK4tRAnG4Kbt269cXF9rbtiQugR44cGbkYu2HDhlG/i/nHnVtB9QIqkdR/HrcBxynB6kXr
um1UJW4QKe5uCglEvJbnl9p+qe/Lf8dOVVznKITRpt0pkaT6QSQYGJEEEexxgTj2luIukidPnrT6
vm2gFLdExivuYnn69GlfIgkOHDiQ78EVbSzusCoGp7hJIAb0OM8cF0/7bU/cEh0XTuOW47huVP5d
nNaK5RS3dBZSIZJmn1dvt01toypxnSVutoh1H1KPHaHq/Oq2X+r78t9xd2DEXHGk0abdKZGk+kEk
GCiRYGiCwCACMQAiAZFA/IFIQCQQfyASSGSDCMQAkUAiG0QgBkAkIBKIPxAJiATiD0QCiWwQgRgg
kglhUMqSDmt5VCKZWky2OBYDU1gkvf5P8l6oK0taLbHb73Lrpv+a5VG/ZtIRyfi3dxjziUiIZEI3
ft28xrrEbt2y6h60RyREMp7tnYr5RCRE0qrEaFBX0raudGhdWdImJUvrltuk3eU2dlpWPE+sW8nT
buV9U2VUU4kUfYo2z5kzJ69+V32OUl2bpopIplrp5GHLJyIhki82bqrEaKqkbap0aN2RQN13qeWm
2t3kiGTLli217a6W2+2lZHD5s+hP1Ckp2vztt99+sT7q2jSVRDKVSicPYz4RCZG0KjGaKmmbKh3a
a+CnlptqdxORpNpd/b6XksHVmhevX7/u2uZeyrBOVpFMpdLJw5hPREIkrUuQ1pW0TQ2evQZ+21K6
1XY3EUmbdgf9llGtXiitK+c61UXSaT1O1tLJw5hPREIkrUqDpkrajlfg91JKd7xF0m8Z1TZ1wYdN
JJO5dPIw5hOREEmrEqOpkrbjFfip5bYpfTtWImlbRrVaJjWq3cX554I///yTSBpu70EunTyM+UQk
RNKqxGiqpG0q8OvKktYFfmq5qXZXqWtHU5GkyqiWL9C+ePEiv2had7E9+kMkzbb3IJdOHsZ8IhIi
aV2CtK6kbSrw68qSpo4S6pbbpN1lUuVRm4gkqCujWgw4cRohBrIYiKrziWSN9sYtltHm1J7zsIgk
tb0HuXTyMOYTkRAJBoQYHBcsWPBVBvOvKRIM1SBkJRAJxpLY24uLt8W9/LEXXXcRl0hAJCASjOLm
zZv5/fpxaiH+Z/vPP/+cC4VIQCQgEkhkgwjEAJFAIhtEIAZAJCASiD8QCYgE4g9EAolsEIEYIJJ6
hrVsrUQem2UPY/wo9YyhEEmb31afYiuYJHKbZQ9j2ePJ0GciwYSKpG1wCCYiqft8GEQyGfpMJGgl
klRZzWfPnuXP4okHxMVzhqK06ZUrV0YCo1rSs+73xTTxoLmiVOrmzZtHPSspNX2q7GldCVFBMFgi
mcplj7u1p5c+p+K62zoRf5gwkaTKaq5cuTJ/GmjxpNBIsgjYbsHR5PdFdcD4/rfffst++OGHxtPX
lT1NlRAVBJPjiGSylz1u257U/JuU5K2uE/GHCRVJL2U1U1XcUr8vH4FE8EfluabT15U9TZUQFQST
QySTvexx2/ak5t9LSV7xhwkVSZOymnHYHDUgduzYkSdJ6hHrbX9fbUPd9HVlT1MlRAXB5LxGMtnK
HrdtT5Nqmm1L8oo/fFWRVDf4hQsX8sI+586dyx80GIfOdUnW9vfVRE5NX4imU9lT0hhOkQxa2eO2
7UnNv5eSvOIPEyqSVFnNuABZLstZLRlbnW+T3z9+/HjUYX+5Dkdq+jLVsqepEqKCYGqKZNDKHrdt
T2r+vZTkFX+YUJGkymrGnSTFXVMhmUi6unKfqd/H3xs3bszevn2bLzMu9Jcvtqemryt7miohKggG
TyRTsexxqj1t+9xLSV7xhwkVSVBXVvPOnTv5hb1IxhjE40J3XbnP1O/j71hGLCumCamULxSmpk+V
PU2VECWSwVr2VC17XNeetn1OxTWRYCBEAiIxiPz/TETZY/EHIoFEnkKDyNcoeyz+QCSQyFNoEPka
ZY/FH4gEEtkgAjFAJJDIBhGIARAJiATiD0QCIoH4A5FAIhtEIAaIBBLZIAIxgCkgklQbBSKRQPyB
SAQakUD8YaqJpJ/StU3K6lZLgMaD6ooyu/H7u3fvjvp9qsxq+e942F6qPGm38qkSeTCWnYq/fkro
to2/VLyn2goiGVqR9FO6tklZ3WoJ0ChYVVQ4jMdSxIMZy79PlVkt/x0S6/bbVPlUiTwYy66Lv35L
6LaNv1S817UVRDLUIhnr0rXVym3VEqCRuNV51v2+25NfU79NlU+VyIOx7Lr467eEbtv4S8V7XVtB
JEMtkn5L1/ZbVjcVaHUiqfttqnyqRB6MZdfFX78ldNvGXyre69oKIhlqkRQy6KV0bS9ldSdKJE1q
0UvkwVh2t/jrt4Ru2/hrUqq5W1tBJEMvkoK2pWvbluENorBQ3amtsRJJqnyqRB68ZXeKv35K6LaN
vzalmqttBZEMtUj6KV3bpKxulTgNFqcIglu3bn1xsX2sRJIqnyqRB2PZqfjrp4Ru2/hLxXtdW0Ek
Qy2SfkrXNimrWyWqz23fvj2fJpYbF8HHQyRBXflUiTwYy07FXz8ldNvGXyreU20FkTi1NcVRPtV/
SASRgEhaoXwqkUD8gUj6QvlUIoH4A5GASCD+QCSQyAYRiAEigUQ2iEAMgEhAJCASEAmIBOIPRAIi
gfgDkUAiG0QgBogEEtkgAjEAIgGRQPyBSEAkEH8gEkhkgwjEAJFAIhtEIAZAJCASiD+M/za0ISWx
NsC2R98isUElsbbANkffIik2rNfwvAZxYPESf5jkIrFnBIg/gEgkMsQfQCQSGeIPIBKJDIg/EIlE
BsQfQCQSGeIPIBKJDPEHEIlEBsQfiEQiA+IPIBKJDPEHEIlEhvgDiEQiA+IPRCKRAfEHEIlEhvgD
iEQiQ/wBRCKRIf6sBBCJRAbEH4hEIgPiDyASiQzxBxCJRIb4A4hkciayl9fXfAFEAnvUAIgEIBIA
RAIiAUAkIBIARAIiAUAkAJEAIBIQCQAiAZEAIBIQCQAiAYgEAJGASAAQCQZPIJ4ZBUDmg0gAEAkG
QyYAiAQgEgBEAiIBQCQgEgBEgmGTCQAiAYgEwNQXidreXl7qwINI7PUCcgZEIiEAMgEmkUgkAiCH
QCSSAJBDIBJJABAJQCQAkQBEAkAOgUgkASCHQCSSAG15+PChlfCV1oMcApHUJMGlS5eyRYsWZTNm
zMjWrFmTPXjw4IvffPjwIVuyZEnP0zfl2rVr2fTp07NVq1bZW+2wPmIdT7b+lOc1VvOdqPVAJCCS
Bknwxx9/ZGvXrs2eP3+eff78Obt48WK2bNmyUb/59OlTtm3bto7zaDJ9G2LQvH79+uQLgHEaZKrr
Y6IGs/ESyWQe1IkERNIlCXbs2JEdP368dtr169dnL1686DiPJtNX2b9/fzZr1qxs5syZ+bxfvnw5
0sbUM47i83v37mXz5s3LVq9ePfL54cOHs9mzZ+fz3bt376hpPn78mO3cuTNf3tKlS7O7d+82ak+3
5YUwd+/enX3zzTfZ/Pnz8yOycnuLo4hp06ZlK1asyG7fvt11XTx79izbunVrvuyYJtp35cqVjuuj
2/qp63u39VUm1Z9O26L6/YULF7K5c+fmbdizZ09+BJs6IqnbLm3WS5P10GabEAmIpGUSLFy4MHm+
+ebNm13n0WT6MidOnMhOnz6dD17xOnv2bD6YNE3W+D4Gqpj21atX+Wcxj/Pnz+efxdFTDITHjh0b
mebgwYPZ5cuX87+vXr066oipSXuqyzt58mR29OjR/LM3b95k69atG9Xu8lHEjRs3ssWLF3ftz8qV
K/OjuGL50ZYY9Lutj+r7VN87tb9Kqj9NRBKn3kLAMY8Y0H/66aekSOq2S9v1kloPbbYJkYBIWiZB
JFgkVuzxxd7f9u3bs3fv3jWeR5vpg+XLl+d7ouW90tiTbSOS8hFDEINYDCBlygNFDFDV79u0p7q8
2LMvT3P//v1R7Y4BrxggeyH2mpuKJNX3Tu2vkupPE5GUjyb+/vvvbMGCBUmR1G2XtusltR763SZE
AiKpSYL4fNeuXdn79+9H9sjjdFXTebSZvjoYlGXURiSdpq+e7igvpzz/sWhPdX7R7/LvQqzFXvqh
Q4eS2yZOPcXeeay3EFvdIF59n+p7k8Ev1Z8mIqkO4t3WYfXIbazWS2o9tN0mRAIiaZEEcV68vDca
A0K3O2I6zaPN9N0GjzZ39XT6vpMMUsvspz2paYpBME7XbNq0Kdu3b1/X5ce1hdgzP3fuXH4KMU4/
tRFJqu+9iKTJOmizjnoRSdv1kloPbbYJkYBIWibB5s2bv9gbjVNUTefRZvogLnRWTyWVxdOLSGKe
cUTUjbhtudsplF7aE3eplad59OhR13bHrdB1fQoRl9sed7+1EUmq700Gv1R/qvPo1MbyLd9xajP6
lRJJ3XZpu15S66HNNiESEEnLJIjzxvEqLmqeOnUq/78gTefRZvogLm7Hb4rfnzlzZtT/T+lFJDHP
4mJxvOJ93H1VEKdH4tRGcOvWrS8utrdtT1wEPnLkyMjF6Q0bNnxx7j/uEgriAm/dnnfcrFDcjRQD
eKy7ugEzJB3XPIqBP9X3JoNfqj/lC9Vx917cTVVtYywzpo15/O///m9+u3hKJHXbJbVe2q6HNtuE
SEAkPSRBDKRxMTL2xGOQePLkSat5NJ2+oLjdNl5xh9TTp0/7Eklw4MCBfC+2aEP5DqW4FTVuAojB
I861x8XkftsTtzzHRfm43TSuC5V/F6dQYjlxuiWWWQxgnbhz505+UTh+F4NdSLlOJHEnUvSxfNRU
1/emg19df4qBN/oTko3+VNsYg/4///nPPA5+/vnnUTdcdOtP3XZJrZe266HNNiESEIkkgNjSTxCJ
JIABVj9BJJIAQ8PXeO6VHAKRSAKASAAiAYgEIBIAcghEIgkAOQQikQQAkQBEAhAJQCSSHRBbIBJJ
INkhtkAkE5wEvZSujWni8d7xbKY5c+Zkv/76a/6QvHjOUaea651K2f7111958aNySdYgHsIXT3Jt
0o5UiViASEAkEySStqVrY5offvgh/+7333/PB/Iff/wxf199smpdKdsoiBXfl4myryGPJu1IlYgF
iAREMkEiaVu6tjpNvC/Xgigvq66U7ePHj/OjkmJZ8e+iRYtG5p1qR6pELEAkIJIJEkmVtuVb696n
Stl+9913+VFHEHUx4vHfTduRKhELEAmI5CuJpG351rr3qTKuUfp06dKl+d9xbSTKqjZtR5OStwCR
gEi+gkjalm+te58qZRtENby43hGntdq0o03JW4BIQCQTKJK25Vvr3qdK2QZxAT3uuipfSG/SjlSJ
WIBIQCRfSSRBm/Ktqfd1pWyDt2/f5ssJGbRpR1BXIhYgEhCJJADkEIhEEgBEAhAJADkEIpEEgBwC
kUgCQA6BSCQBQCQAkQBEAhAJADkEIpEEgBwCkUgCgEgAIgGIBCASAHIIRCIJADkEIpEEgBwCkUgC
gEgAIgEgh0AkEgGQOyASCQHIGRDJQCeGl5dXsxdAJLDnC4BIQCQAiAQgEgBEAiIBQCQgEgBEAiIB
QCQAkQAgEhAJACIBkQAgEhAJACIBiAQAkYBIABAJiAQAkYBIABAJiAQAkQBEAoBIQCQAiAREAoBI
QCQAiAQgEgBEAiIBQCQgEgBEAiIBQCQAkQAgEhAJACIBkQAgEhAJACIBiAQAkYBIABAJiAQAkYBI
ABAJiAQAkQA9CaT6AkAkAJEAIBJ8HZkAIBKASAAQCYgEAJGASAAQCYZNJgCIBCASAEQyCAOq1/C8
IO7FPZHYK4dtbh1gDLa5KJBMsO31HX1te5EgmSAG9Bl9xYBokFAQA/oMIpFQEAP6DCKRUBAD+gwi
sTIhBvQZRAIJBTGgzyASCQUxoM8gkimQUK9fv87+67/+K5sxY0Y2c+bMbPv27dmbN296Xs61a9ey
6dOnZ6tWrTLg6OPA9rnT/4SeNm2auCcS9BIwGzZsyH799dfs8+fP+Sv+3rhxY8/LiWS6fv26QVYf
J1Wff//99+zAgQPinkjQS8BEAjT5rMz+/fuzWbNm5Ucw69evz16+fNlxL69bO+7du5fNmzcvW716
9cjnhw8fzmbPnp3Pd+/evaOm+fjxY7Zz5858eUuXLs3u3r3bqD3dlhfC3L17d/bNN99k8+fPzy5d
ujSqvcXeZeyhrlixIrt9+zaRTOE+RzysXLky++uvv8T9FI97IhnnI5KCy5cvZ999913X+Zw4cSI7
ffr0yBHM2bNn82Bvmrjx/Z49e/JpX716lX8W8zh//nz+2adPn/IAP3bs2Mg0Bw8ezNsVXL16NVu2
bFmr9lSXd/Lkyezo0aP5Z3Eab926daPaXd67vHHjRrZ48WIimcJ9jphJHY2IeyJBTaA/fvw4mzNn
zsjeVPwdn3Vj+fLl+Z5Sea9p7ty5rRKqvOcUxHnlCO4y5SCOBKp+36Y91eXFHlp5mvv3749qd+zF
FQns1NbU73McjTx//rz2N+KeSFAT6Fu3bs33boo9m+PHj2fbtm3rOp9OFyTLp8KaJFSn6esufNad
auulPdX5Rb/Lv4u9sXgfiX7o0CEimcJ9jp2mNWvWJOcj7okENYEed2uV93ri7zjn2o1OwT1qQ/WQ
UKm7ZeoSqpf2pKYJ4vxynE7YtGlTtm/fPiKZon0+depUfq0hhbgnEtQEelUaIZK4gNeNuAhXPaQO
GfWTUDHP9+/fd51myZIlXQ/xe2nP2rVrR03z6NGjru1+8ODBlBmAieRL4ug7Bs4U4p5IUBPocUHu
3Llz+cW+CNq4IBd3dnQjToPFXlxxKuzMmTN5wPeTUDHP4iJgvOJ93IVSEBcd47A7uHXr1hcXHdu2
5+LFi9mRI0dGLjrGDQfl38X84w6WIC4+pu5iI5LJ2+e4JlFcjK5D3BMJagL9w4cPuUxibyZeIZH4
rI7itsN4xZ0iT58+7SuhgrhrJm5LjDbEdZtyckd74j9KRmDHRca4SNhve+JaUFycjFsv446X8u/i
8D6WE6ceYplFchHJ1OtzbN9ue/3ifurFPZEYRCAG9BlEIqEgBvQZRCKhIAb0GURiZUIM6DOIBBIK
YkCfQSQSCmJAn0EkEgpiQJ9BJBIKYmBy96muX+IeRGIQgRhoJJJuNUHEPYjEIKLf47Auug2+U/U1
WWLta09PJBBk+u2I5CsfkRAJkQztIFJXXrOu1GcvpUNT38c8o2LcwoULR573U62DXTd9qpSoGHCN
pEksff/99/lDEss5snnz5kY5Ubfc8mdNYlWsE8mkGUTqymvWlfrspXRo6vuYZzy4rqjsVn0CaWr6
VClRMeCurSaxFPEcxa7iu3hwYuREUTU0lRNNRZKKVbFOJJMqoerKa9aV+uyldGjq+07zLLc7NX2q
lKgYIJKmsRQDeQzWMXj/9NNPjXOiqUhSsSrWiWRSJVRdec26egS9lg6t+z6VfG1Lk1ZLiYoBImka
S8VgHo9cf/v2beucaBLLdbEq1olk0g0i3cprthVJqnRo6vtU8vVSmlRyEUkvsRhs2bIlPwKZCJGI
dSKZMoNItbxmXanPXkqHpr5PJV9q+jalRMXAcPc5FUtRcTCuUUT10PKpraY5UV3u8+fPR32WilWx
TiSTKqHqymvWlfrspXRo6vuUSFLTp0qJigEiaRJLcbH922+/HTWoP3nypFVOlG9iefHiRX4TSfn7
VKyKdSKZVAlVV16zrtRnL6VDU9+nRNJk/nWlRMUAkTSJpYj58u2/8Xd83yYnip2yyKs4iom8qrYl
FatinUgMIhAD+gwikVAQA/oMIoGEApFA3BOJhIIY0GcQiYSCGNBnEImEghjQZxCJlQkxoM8gEkgo
iAF9BpFIKIgBfQaRSCiIAX0GkUgoiAF9BpFAQkEM6DOIREJBDOgziERCQQzoM4hEQkEM6DOIBBIK
YkCfQSSSCra9vmOctr1IkFSwza0D9LXNRcEYr2Cv4XlB3It7IoG9UgBjMQZYBSASAEQCIgFAJCAS
AEQCIgFAJACRACASEAkAIgGRACASEAkAIgGIBACRgEgAEAmIBACRgEgAEAlAJACIBEQCgEhAJACI
BEQCgEgAIgFAJCASAEQCIgFAJCASAEQCIgFAJACRACASEAkAIgGRACASEAkAIgGIBACRgEgAEAmI
BACRgEgAEAlAJACIBEQCgEgwcAKpvgAQCUAkAIgEX0cmAIgEIBIARAIiAUAkIBIARIJhkwkAIgGI
BACRDMKA6jU8L4h7cU8k9sphm1sHGINtLgokE2x7fUdf214kSCaIAX1GXzEgGiQUxIA+g0gkFMSA
PoNIJBTEgD6DSKxMiAF9BpFAQkEM6DOIREKNNQ8fPhyo+YgBfZ7scTsVcoFIJjChPnz4kC1ZsqTv
5Vy7di2bPn16tmrVqp6+rw2CRB9mzJgxJutqrOZjUJ06cT+scVudZ9MYGqRYI5IJSqhPnz5l27Zt
G5ONH8l2/fr1nr/vJyHHKnin6oBLJL3H/bDGba/zJJIhTKj169dnL168aLzx9+/fn82aNSubOXNm
Pu3Lly9HllH3rJtO33f7XduE7Lbsw4cPZ7Nnz87bu3fv3pHPv//+++zWrVuj9jg3b948pZ9TRSS9
xf1Uidtnz55lW7duzfM2xLh06dLsypUro9py7969bN68ednq1auT/f748WO2c+fOfH4xr7t373bt
c7f+EMkUSqibN282HmhOnDiRnT59Ovv8+XP+Onv2bB5Mve59jVVCdvo+2nb+/Pm8nbH3eenSpezY
sWP5d69evcrWrFmTfxenNxYvXpw9fvzYEYm4n7Jxu3LlyuzixYsjuRt5HNIot2PPnj35d7GcVL8P
HjyYXb58Of/76tWr2bJlyzr+rq4/RDIFB5Emv1m+fHm+J1LeK5k7d+5AiiTOZ0fwlonEKwf4yZMn
86D+6aefnNoS90MXt9OmTRs1fXF2oUm/QxzVdnb6Xao/RDKECVUOvII4TB5EkUS7qofn1fZHkIcI
3759SyTifsrHbZy6iiOJHTt25DuFqXbW9buc93XTNekPkQxZQnUKnn6SppeE7HY+uDqvJsG6ZcuW
fM+KSMT9VI/bCxcu5NOcO3cuP60Xp68mQiQTKQ0imSQJtWLFii9ObZVvEexXJM+fPx+zPbto6/v3
77v+/syZM/m520gsp7bE/VSP22+++WbUfOva3KTfcdt0k1Nbqf4QyRAmVFxsP3Xq1MgFuwjq8n34
vRzGF7dVxh00cVdJrwkZd4/EOd5CdNHWo0ePjrQ13sedOkHsjX377bejgv3Jkycd50Mk4n4qxO3C
hQtH7tJ69OhRftE+1c7qPKsX22/cuJH/HXeSdbvYXtcfIhnShAqK23/jFXdsPX36tGeRRDJGUsbh
bwgpbmfsNSHj4mMcHZWPkA4cOJDvicVnkezF3Sjbt28fdRtl/B3fd5sPkRDJZI/bO3fu5Be5o90x
6McdV6l2VudZ/k3cNRbtifnF9Zb79+93nVe3/hCJQQRiQJ8xqWJANEgoiAF9BpFIKIgBfQaRSCiI
AX0GkViZEAP6DCKBhIIY0GcQiYSCGNBnEImEghjQZxCJhGrPVC1FKwb0GePPRI8fRDKgCTUVym8O
4/YjksFe1teefqKY6CdGEMmAJtRUKL9JJNYbkQzHUSKRTMDGG9Tym/HsouJZRvFgutu3b3ftW6oP
dfNKLafXNvYz33iw3e7du/NnE82fPz+vKEckY9/ntuVs28R36km6TbbxWMZIPznSqR/x9OF4CGT8
vlM9+17LcRPJJE2oQS2/WQ7OeMJoXUW1VB/q5lX3XT9t7Ge+Uf2ueFrqmzdvsnXr1hHJGPe513K2
TeM7JZLUNh7rGOknRzr1I6RUyKF4gGVBv+W4iWSKHE4OQvnNCPIiYXuh3Ie6edV9108b+5lvHPmV
HwUeT1UlkrHtc6/lbJvGd0okqW08ETHSNEc69aNuTOi3HDeRTFKRDGL5zdgris8ioQ4dOpTsX10f
6uZV910/bexnvtV1GAMKkYxtn3stZ9s0vlN5k9rG4xEjveZIk3WaqojYphw3kUzChBrk8psR+HH6
YNOmTdm+ffu6/i7Vh9S8un3Xbxt7nW+qnDGR9N/nXsvZjpdI2uZH2xjpN0faiKTfctxEMgkTajKU
33zw4EFt8KX60HRe1e/Gqo1t57t27dpRpwaimh2RdO9TXb+6fddrOdum8Z0qxZvaxmMdI2OVI03G
hH7LcRPJJBTJoJbfjOniTpKgejGvbR/q5lX3XT9t7Ge+cVH0yJEjIxdSN2zYQCQJkXS7G6hbn3st
Z9s0vlOleFPbeKxjpJ8caSuSVDnuiS5lTSQTIJJBLb8Zh9kxfXF7YRHkvfShbl6p5fTaxn7mGxw/
fjw/Px+3f8aF37EUSbfBd6q+utFLOdum8Z0qxdtkG49ljPSTI21FEtSV457oUtZEMgEigRgYxiMS
DGfciwaDCMRAV5GIexCJQQRiQJ9BJBIKYkCfQSQSCmJAn0EkkFAQA+IeRCKhIAb0GUQioSAG9BlE
IqGmPMNWMphIQCQYl4QqCtrEUz+/yoZtkehtpuv22/LfE13y06A6OH2u/gfGyIH4X+S7du3K/vrr
r1G/jYc2RmGpeNR68T/aoz5I3fwmungTiOSrJlSn6maTYUDrVUDDPLASSf3nIZB46m1UHix/FrU/
4gGOxbOh/vjjj2zRokX5E3WtZyIZ+oTqtufUrUxmMU259G436sqE1h1ZxHSxZzhnzpy8ylrdkUW0
qyh7GqVQuz33qNPf1b5HBbkqUZluwYIFX+yhEsnUFEkQDxmMmC2IhzTGQwirhEy6xT+REMnQJ1ST
MpnV0rtVUmVCuw3yMU3sERZPNI0nsNYJIR6l/fr16/z3v/32W/bDDz80Fkn173h6arVOdbTnxx9/
dEQyRCIJyiKJBxzG03utZyJBi4RqUiazWmazSqpMaLfBvBBDQbV8aPXv8hFILK98naetSIqCPmVi
j/PPP/8kkiERSQgjyuvGjlJB3ePUrWcikVBdPh+LMpmpMqFNL35Xy4emLrZ3a2fTeUTNhsePH49I
rO7UHZFM/rivvubPn5+f1o2j6II4bWo9EwlaimQsymSmyoR2m1+qDnWqHd2qsDWdRxQKirt2gjid
98svvxDJEMR9HAXHNbaoDFglrp3FadYqIZuiUJT1TCQSqvL5WJTJTJUJ7TaYR9W2ctLGaaU6CRRH
D0U748J4PyKJZcceaAwscaNAFDEikuGI+xBDFI/6/fffR31+6NCh/FpZlf/85z+jqigSCZFIqBKp
MplNkiRVJrTpxfaYpk4CGzduzO/xj9/H8tpebO9U8jOORP71r3+NOk9OJFM/7osjk7iWF/XMC969
e5dfN4w8+Pvvv0du7Ii7CqPqoPVMJBKqy+d1ZTKbJkldmdDU6aU4Gojz1XH3V93pqvg+fhu/CalU
b1NO/d2p5Ofdu3fz30zF//VOJOnPo6zud999N+qzuAj/73//O8+HOG0b187KpXitZyIZ+oQaZOLU
Uvl01UQQwouL7mJAn0EkmIQJFbcZx224xf8/iSOjONU1UcRy40gqzouLAX0GkWASJtTNmzfz0wZx
qinOQf/888+jbsUcb+KaSZwim2oX2YkExj4ikVAQA/oMIpFQEAP6DCKRUBAD+gwisTIhBvQZRAIJ
BTGgzyASCQUxoM8gEgkFMaDPIBIJBTGgzyASSCiIAX0GkUgoiAF9BpFIKIgBfQaRSCiIAX0GkUBC
QQyIexCJpIJtr+8Yn20vEiQVbHPrAH1tc1EwxivYa3heEPfinkhgrxTAWIwBVgGIBACRgEgAEAmI
BACRgEgAEAlAJACIBEQCgEhAJACIBEQCgEgAIgFAJCASAEQCIgFAJCASAEQCEAkAIgGRACASEAkA
IgGRACASgEgAEAmIBACRgEgAEAmIBACRgEgAEAlAJACIBEQCgEhAJACIBEQCgEgAIgFAJCASAEQC
IgFAJCASAEQCEAkAIgGRACASDJxAqi8ARAIQCQAiwdeRCQAiAYgEAJGASAAQCYgEAJFg2GQCgEgA
IgFAJIMwoHoNzwsAkdgrh20OEIkBBbY9QCQGEogBgEgMIhADAJHAIAIxABCJQQRiACASgwjEAEAk
BhGIAYBIMPSDyMOHD21cIgGI5GsOIu/evcu2bt2azZw5M5s1a1b2/fffZ2/evJk0/ZoxY8aYrpup
PNgSCYgE4zKIHD58ODt06FD2+fPn/PWf//wnO3DgwFANjsMywBIJiATjMohs3Lgxe/To0cj7T58+
ZZs3b66dz/nz57OFCxdm06ZNy6ZPn55dv379CznNnj07P8LZu3fvyOeLFi3K3r59m//9/PnzfF5/
/PFH/v7169f59524du1avpxY3ooVK7Lbt2+PtKX6TKlO/Sx/FrLcvXt39s0332Tz58/PLl26VHtE
0q0vde0iEoBIhkokMaDG4Fr9rG4+cSrs5cuX+fuQSAymBWfPns1FE/MMKcVAfezYsfy7f//739lv
v/2W//3rr7/mp6Xi98X7nTt3dlxmWVY3btzIFi9e3LVfKZGcPHkyO3r0aN6+OIW3bt26riKp60uq
XUQCEMnQiKQsgbrPyvMpJNJp3qtWrfpCTMUAe+HChWzXrl353//zP/+T7dixI38FP/zwQz5Qd2Le
vHnZ5cuXG/UrJZLVq1dnHz9+HHl///79riKp60uqXUQCEMnQiCROy7QVSd1nMW31lFOxjMePH2cr
V67M/45TQQ8ePMgWLFiQv1+6dGl+uqsTsbcf84mBPa7n9COSat9CFN1EUteXVLuIBCCSoRFJp9NY
qVNbdZ91ElOZOXPm5KeUCoHEtZa4RlO878a9e/eyq1evZps2bcr27ds3ZiKpft+mL3XtIhKASIZG
JDEA/v333yPvP3z4kK1fv75nkcSRxvv377tOv23btuy///u/R05pFae3ivcp4iim7uJ49X1xUb9g
7dq1o05thcS6zS/Vl7p2EQlAJEMjkrgrqbj4HK9z587VnqZJieTEiROj5hfvy2I6depUNnfu3OzM
mTP5+19++SX/PyxxUbsby5Yty++QCqoX92PauGZTyKF8AfzFixf5jQHl9l28eDE7cuTIyMX2DRs2
dBVJqi917SISgEiGRiSvXr3KB9O4gypeW7Zsyf+TYq8iCeL/ocTpsZhfDOSxjIL/+7//G3Xbb3Gx
+8mTJ12XGaePli9fPnK7cTF4B3EXVdH28oAev12yZEn+22r7jh8/nsssbuuNO7PqjnDq+lLXLiIB
iGRoRAIxABAJDCIQAwCRGEQgBgAiMYhADABEYhCBGACIBAYRiAGASAwiEAMAkRhEIAYAIjGIQAwA
RILkIDJWg0u/8xnP6Q2g1gNAJJNgEBlkkcA6Aohkgo5IUmV048GIUcUwHpQY9UPu3r3bdT51y0mV
uw3qStw2mb7XPhIJQCToUyR1ZXQPHjw4UhEwanDE0297EUmq3G2qxG1q+n76SCQAkaBPkdSV0Q1x
VEvP9iKSVLnbVInb1PT99JFIACJBnyKp+75pCd5+y92mStympu+nbUQCEAkmoUiq36dK3KamJxIi
AYhkQEUShaJ6ObXVttxtqsRtanoiIRKASAZUJHGx/caNG/nft27d6nqxvd9yt6kSt6npiYRIACIZ
UJF8+PAh2759ey6KKDEbF7k7/a7fcrdBXYnbJtMTCZEARGIQgRgAiMQgAjEAEIlBBGIAIBIYRCAG
ACIxiEAMAERiEIEYAIjEIAIxABCJQQRiACASTIFB5OHDh+P6exAJQCRTZBDp9r/K43+st6H6e4Mi
kQBEMoQi6ac9BkEiAYhkgAeR/fv358+1mjdvXnbhwoVWz6Z69uxZ/iysKL8bz9eKErxXrlypPSKp
1hpJzafT7+Pfv/76K1uwYEH+DLAy8WTgeIJwQV3Z3m7rI34bbYmHRZYLYcVy7927l6+rKLBFJACR
DL1Iomxt8STdeDBiDI5tRLJy5cr8abzFk3pPnz6dD7J1Iuk03zbzKb/ftWtX/nTgap9CHkGqbG+V
mFcsu2hHTB916svL3bNnz8j6IhKASIZeJFHWtrxHf/fu3b6fllsuTNVUJG3mU37/+PHj/KikqJMS
/y5atGjkKCJVtrdKPNW4XOsk/o6nDJeXWy3VSyQAkQy1SFJla5uIJE71RK2SHTt25ANxE3l0mm/T
+VTff/fdd/lRRxBHNXGKrNy/urK9dfLqtI4m82BMJCASTIhImgz45c/imkoUuDp37lx28+bN/HRP
LyJpM5/q+6tXr+bXVIK4NhLT14mhjl7WB5EARDLUIvn222+zd+/ejbyvlq1Nlc2Ni/TlsrjV75uK
pM18Or1fuHBhfm0kTmuVSZXtrRK/r57aKt96TCQAkRBJhd9++y2/S6lb2dpU2dwYwIu7q0JCa9as
aSSPuCMqrjUUg3ZqPtXfV/sTF9Dnz5//xYX0VNneKvH9qVOnRn5/5syZvMojkQBEYgXWDCJxZ1Lc
IfXPf/4zH8zblM29c+dOfvE6fhOnpi5fvtxIJDHgx55+sbefmk/199X+vH37Nv8uZFglVba3SnH7
b7zijq2nT58SCUAkaDOIGHDEAEAkIBLYrgCRfL1BpO1zsEAkAJEYRCAGACKBQQRiACASgwjEAEAk
BhGIAYBIDCIQAwCRYLIMInUldJXjJRKASAwiSepK6CrHSyQAkRhE+mqXcrxEAhDJJBlExrvUbtQK
iYcyxvO6yg+B7FZCt9t3g1SOl0gAIiGS/4+JKLUbg39RVbB4CGS3+U+GcrxEAhAJkZSYiFK71dK0
TeuMDGo5XiIBiIRISkxkqd2xEMkglOMlEoBIiKRGJE0G815L7fYrkkEpx0skAJEQSYmJLLXbr0gG
pRwvkQBEQiQlJrLUbqfP6kroDmo5XiIBiIRIKkxUqd1On9WV0B3kcrxEAhAJkRhwxABAJCASEAlA
JAM5iCi1KwYAIoFBBGIAIBKDCMQAQCQGEYgBgEgMIhADAJHAIAIxABDJZBtElL0VAwCRGET6YiLL
3hogrSeASKbgIJJ6gCKIBCCSKTKIxLOzimdpxVNwb9++nT19+jSvRlglqgdGgagoX9tLCd1Tp051
/H1BXbnbTu3s1Le634kBaQQiwTgMIuUB/caNGyOVAeMpwNVBOMTx448/jsyvbQndLVu2dP19qtxt
t3ZWl1X3OzEgjUAkGIdBJJ76G0/RrRKFoDZt2jTqs6jn/ueff47Mr20J3brfp8rddmtndT51vxMD
0ghEgnEYRGKvPb6LgfzQoUOjvovTUFHvPLh//34ukrr5tSky1elIoq7cbV07y/Op+50YkEYgEozT
IBJ10IsjkH379o18fuTIkWzXrl353zt37sx++eWXcRNJk3K33drZqYZ8p9+JAWkEIsE4DyIPHjwY
9bsoABVVB1+/fp1fBP/w4cO4iaRNudtqO7v1rfo7MWBdgEgwDoNIVBqMO52C6gXw4kjkX//6V7Zn
z55WYkiVva1+lip3W9fO8nxS/REDAJFgjAeROA20fPnykVtyi0G44O7du/m01f+p3k8J3W7zqCt3
W9fO8nxS/REDAJFgggeRGMzjojuIBCASg0jraeIUUxwluPuJSAAiQU+DSFzn2Lhx46iL7CASgEgM
IhADAJHAIAIxABCJQQRiACASgwjEAEAkBhGIAYBIYBCBGACIxCACMQAQiUEEYgAgEoMIxABAJDCI
QAwARGIQgRgAiMQgAjEAEIlBBGIAIBIYSGDbA0RiQIFtDhDJ4A0sXsPzAvD/8v8AKbo9tfAYvNgA
AAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-11-23 14:57:51 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Gail Quinn">
<APPENDIX ID="APP-01" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Clare Jess" NO="1">
<TITLE MODIFIED="2012-11-05 12:02:07 +0000" MODIFIED_BY="Clare Jess">Chinese Biomedical (CBM) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Clare Jess">
<P>The search strategy in the Chinese Biomedical Base (CBM Base)<BR/>#1 gestational trophoblastic tumour<BR/>#2 gestational trophoblastic disease<BR/>#3 invasive mole<BR/>#4 choriocarcinoma<BR/>#5 hydatidiform<BR/>#6 persistent trophoblastic disease<BR/>#7 treatment<BR/>#8 chemotherapy<BR/>#9 etoposide<BR/>#10 methotrexate<BR/>#11 actinomycin<BR/>#12 cyclophosphamide<BR/>#13 vincristine<BR/>#14 chlorambucilum<BR/>#15 doxorubicin<BR/>#16 melphalan<BR/>#17 hydroxyurea<BR/>#18 Hammond<BR/>#19 Goldstein<BR/>#20 CHAMOCA<BR/>#21 EMA/CO<BR/>#22 (#1 or #2 or #3 or #4 or #5 or #6) and (#7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-11-05 12:07:32 +0000" MODIFIED_BY="Clare Jess" NO="2">
<TITLE MODIFIED="2012-11-05 11:41:06 +0000" MODIFIED_BY="Clare Jess">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-05 11:50:23 +0000" MODIFIED_BY="Clare Jess">
<P>#1   MeSH descriptor Gestational Trophoblastic Disease explode all trees<BR/>#2   gestational and trophoblastic and (neoplasm* or tumor* or tumour* or disease*)<BR/>#3   GTT or GTD or GTN<BR/>#4   choriocarcinoma*<BR/>#5   ((hydatidiform or invasive) and mole*)<BR/>#6   (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7   MeSH descriptor Antineoplastic Agents explode all trees<BR/>#8   MeSH descriptor Antineoplastic Combined Chemotherapy Protocols, this term only<BR/>#9   chemotherap*<BR/>#10  (etoposide or methotrexate or dactinomycin or actinomycin or cylophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA/CO or EMA-CO or CHAMOCA)<BR/>#11  (#7 OR #8 OR #9 OR #10)<BR/>#12  (#6 AND #11) </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Clare Jess" NO="3">
<TITLE MODIFIED="2012-11-05 11:51:02 +0000" MODIFIED_BY="Clare Jess">MEDLINE (Ovid) search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Clare Jess">
<P>1   exp Gestational Trophoblastic Disease/<BR/>2   (gestational trophoblastic adj (neoplasm* or tumor* or tumour* or disease*)).mp.<BR/>3   (GTT or GTD or GTN).mp.<BR/>4   choriocarcinoma*.mp.<BR/>5   ((hydatidiform or invasive) and mole*).mp.<BR/>6   1 or 2 or 3 or 4 or 5<BR/>7   exp Antineoplastic Agents/<BR/>8   Antineoplastic Combined Chemotherapy Protocols/<BR/>9   chemotherap*.mp.<BR/>10 (etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA).mp.<BR/>11 7 or 8 or 9 or 10<BR/>12 randomized controlled trial.pt.<BR/>13 controlled clinical trial.pt.<BR/>14 randomized.ab.<BR/>15 placebo.ab.<BR/>16 drug therapy.fs.<BR/>17 randomly.ab.<BR/>18 trial.ab.<BR/>19 groups.ab.<BR/>20 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19<BR/>21 6 and 11 and 20<BR/>22 exp animals/ not humans.sh.<BR/>23 21 not 22</P>
<P>key:<BR/>mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier<BR/>ab=abstract<BR/>fs=floating subheading<BR/>pt=publication type </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Clare Jess" NO="4">
<TITLE MODIFIED="2012-11-05 11:52:16 +0000" MODIFIED_BY="Clare Jess">EMBASE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="Clare Jess">
<P>1 exp trophoblastic tumor/<BR/>2 (gestational trophoblastic adj (neoplasm* or tumor* or tumour* or disease*)).mp.<BR/>3 (GTT or GTD or GTN).mp.<BR/>4 choriocarcinoma*.mp.<BR/>5 ((hydatidiform or invasive) and mole*).mp.<BR/>6 1 or 2 or 3 or 4 or 5<BR/>7 exp antineoplastic agent/<BR/>8 exp chemotherapy/<BR/>9 chemotherap*.mp.<BR/>10 (etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA).mp.<BR/>11 7 or 8 or 9 or 10<BR/>12 crossover procedure/<BR/>13 double-blind procedure/<BR/>14 randomized controlled trial/<BR/>15 single-blind procedure/<BR/>16 random*.mp.<BR/>17 factorial*.mp.<BR/>18 (crossover* or cross over* or cross-over*).mp.<BR/>19 placebo*.mp.<BR/>20 (double* adj blind*).mp.<BR/>21 (singl* adj blind*).mp.<BR/>22 assign*.mp.<BR/>23 allocat*.mp.<BR/>24 volunteer*.mp.<BR/>25 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24<BR/>26 6 and 11 and 25</P>
<P>key:<BR/>mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-10-19 13:30:56 +0100" MODIFIED_BY="[Empty name]">Risk of bias assessment</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-14 16:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of included RCTs in accordance with guidelines in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) as follows.</P>
<SUBSECTION>
<HEADING LEVEL="5">Randomisation</HEADING>
<P>The method of randomisation was noted on the data extraction form. We assessed the randomisation as:<BR/>
</P>
<UL>
<LI>low risk of bias: e.g. a computer-generated random sequence or a table of random numbers;</LI>
<LI>high risk of bias: e.g. date of birth, clinic id-number or surname;</LI>
<LI>unclear risk of bias: e.g. details not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment</HEADING>
<P>We assessed the concealment of allocation sequence from treatment providers and participants as:<BR/>
</P>
<UL>
<LI>low risk of bias: e.g. where the allocation sequence could not be foretold;</LI>
<LI>high risk of bias: e.g. the computer-generated random sequence was displayed so treatment providers could see which arm of the trial the next participant was assigned to, or kept in a sealed opaque envelope;</LI>
<LI>unclear risk of bias: allocation concealment not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blinding</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received, as well as whether the outcome assessors were blind to the group allocation. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed the methods of blinding as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants, personnel or both;</LI>
<LI>low, high or unclear risk of outcome assessor bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Incomplete outcome data</HEADING>
<P>We recorded the proportion of participants whose outcomes were not reported at the end of the study and we noted if loss to follow-up was not reported.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias, if fewer than 20% of patients were lost to follow-up and reasons for loss to follow-up were similar in both treatment arms;</LI>
<LI>high risk of bias, if more than 20% of patients were lost to follow-up or reasons for loss to follow-up differed between the treatment arms;</LI>
<LI>unclear risk of bias if loss to follow-up was not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Selective reporting</HEADING>
<P>We assessed the methods of outcome reporting as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest have been reported);</LI>
<LI>high risk of bias (where not all the study's pre-specified outcomes were reported; one or more reported primary outcomes were not pre-specified; outcomes of interest were reported incompletely and so could not be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other bias</HEADING>
<P>We described for each included study any important concerns we had about other possible sources of bias. We assessed whether each study was free of other problems that could put it at risk of bias and assessed the risk as follows:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 new studies included in qualitative or quantitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 of full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;616 of records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;661 of records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 full-text article excluded as not RCT&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 new studies included in qualitative or quantitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;651 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;699 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;16 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>